STOCK TITAN

Globa Terra redemptions leave about $10.8M in trust

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Globa Terra Acquisition Corp. (GTERA) reported third-quarter net income of $1.48 million versus $1.31 million in 2025, and nine-month net income of $4.17 million versus $1.31 million. Income came from trust interest; nine-month formation and operating expenses were $550,315. At September 30, 2026, $183.1 million was held in trust, with $104,902 outside it and $1.26 million in deferred service-provider obligations. Management said these conditions raise substantial doubt about continuing as a going concern, and its plans do not alleviate that doubt.

After quarter-end, shareholders approved an extension; deposits moved the business-combination deadline to December 9, 2026, with further monthly extensions possible through July 9, 2027 if contributions are deposited. Holders redeemed 16,477,996 Public Shares, leaving 1,021,554 and approximately $10.8 million in trust. On November 8, 2026, GTERA signed a conditional agreement with Nature’s Ledger, which will use reasonable best efforts to raise $10 million through a PIPE. Closing requires shareholder and Alberta court approvals, an effective registration statement and Nasdaq listing approval. The Nasdaq delisting hearing is scheduled for December 1, 2026; the request stays suspension pending the panel’s decision.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month net income: $4.17 million versus $1.31 million in 2025.

Negative

  • Major pointGoing-concern doubt is not alleviated; $1.26 million in deferred obligations.
  • Major pointNasdaq delisting determination; December 1, 2026 hearing, with suspension stayed pending the panel’s decision.

Filing Explained

The fully advanced seven-hundred-fifty-thousand-dollar note could convert at the lower contractual price, with two hundred fifty thousand extra shares, subject to approval.

The agreed combination remains unclosed; if completed, target holders would receive Pubco shares, with up to 6,557,772 additional shares tied to price or EBITDA milestones over five years.

Issuing those shares would increase the total share count and reduce existing holders’ percentage ownership, absent offsetting changes.

The full $750,000 principal had been advanced by November 9; before closing, Nature’s Ledger may elect to convert all unpaid principal and accrued interest at the lower of $5 per share or the lowest effective price in a qualifying financing, plus 250,000 shares for no additional consideration.

That conversion requires approval by holders of a majority of GTERA’s outstanding ordinary shares, and the Sponsor agreed to vote in favor.

The PIPE terms also allow up to 3,000,000 additional Pubco shares for investors, plus a matching number tied to the Sponsor’s forfeiture of up to 500,000 shares, as the parties determine.

The agreement requires Nature’s Ledger and BCCo to deliver PCAOB-audited financial statements by December 31, 2026; GTERA may terminate if they are not delivered by January 31, 2027.

Nine-month net income $4.17 million Nine months ended September 30, 2026; $1.31 million in 2025.
Cash outside the Trust Account $104,902 As of September 30, 2026.
Deferred service-provider obligations $1.26 million As of September 30, 2026.
Public Shares redeemed 16,477,996 shares In connection with the November 2026 Extension Proposal.
Aggregate redemption amount Approximately $173,652,702 Redemption of Public Shares in connection with the November 2026 Extension Proposal.
Public Shares remaining 1,021,554 shares After the November 2026 redemptions.
Trust Account after redemptions Approximately $10.8 million After the November 2026 redemptions.
Proposed PIPE financing $10 million Nature’s Ledger will use reasonable best efforts to raise this amount in connection with the proposed business combination.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Trust Account financial
"cash held in the Trust Account"
A trust account is a special bank or brokerage account where assets are held and managed by a designated person or firm (the trustee) for the benefit of another person or group (the beneficiary). It matters to investors because it separates assets from personal or corporate funds, can protect assets, control how and when money is used, and may affect tax or legal rights—think of it as a locked drawer opened only under agreed rules.
PIPE Financing financial
"Nature’s Ledger will use its reasonable best efforts to raise $10,000,000"
Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.
pre-money equity value financial
"a pre-money equity value of Nature’s Ledger of $323,775,000"
The pre-money equity value is the total worth assigned to a company’s outstanding shares immediately before new investment is added; it represents the company’s equity “slice” before the new money changes the pie. Investors use it to calculate how much of the company they will own after a financing round and to judge whether the price per share is fair, similar to agreeing on the size of a pie before cutting it into new portions.
earnout consideration financial
"additional Pubco Common Shares as earnout consideration"
Earnout consideration is the portion of a purchase price that one party pays later only if the acquired business meets agreed future targets, like sales or profit goals. Think of it as a performance-linked bonus that shifts some risk from the buyer to the seller; investors watch earnouts because they affect how much value will actually be paid, influence future cash flow, and can change reported earnings or liabilities if targets are missed or met.
Staff Delisting Determination regulatory
"received a Staff Delisting Determination from Nasdaq"
A staff delisting determination is a formal finding by exchange or regulatory staff that a listed security no longer meets the rules required to stay listed, similar to an official notice that a rental property no longer qualifies for occupancy. It matters to investors because it often precedes removal from the exchange, which can sharply reduce a stock’s visibility, trading liquidity and value, and may trigger urgent choices like selling, appealing the decision or seeking alternative markets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the proposed GTERA and Nature’s Ledger deal?

On November 8, 2026, GTERA signed a business-combination agreement with Nature’s Ledger, subject to closing conditions. The agreement assigns Nature’s Ledger a pre-money equity value of $323,775,000 and BCCo $825,000; eligible Nature’s Ledger holders may receive up to 6,557,772 additional Pubco Common Shares tied to specified share-price or EBITDA milestones over five years. Nature’s Ledger will use reasonable best efforts to raise $10 million through a PIPE.

What is GTERA’s business-combination deadline?

GTERA’s current deadline is December 9, 2026. The Board may extend it monthly through July 9, 2027, with each additional extension requiring a Trust Account deposit equal to the lesser of $0.04 per non-redeemed Public Share and $50,000.

How many GTERA Public Shares were redeemed in the November extension?

Holders redeemed 16,477,996 Public Shares for approximately $10.54 per share, or approximately $173,652,702 in total. That left 1,021,554 Public Shares outstanding and approximately $10.8 million in the Trust Account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(MARK ONE)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-42736

GLOBA TERRA ACQUISITION CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands
 
N/A
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
382 NE 191st Street #952377
Miami, Florida
 
33179
(Address of principal executive offices)
 
(Zip Code)

+52 55 8975 9325
(Registrant’s telephone number, including area code)

Not applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each
exchange
on which
registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, three-fourths of one redeemable warrant, and one right to receive one-tenth of a Class A ordinary share
 
GTERU
 
The Nasdaq Stock Market LLC
Class A ordinary shares included as part of the units, $0.0001 par value
 
GTERA
 
The Nasdaq Stock Market LLC
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share, $0.0001 par value, at an exercise price of $11.50
 
GTERW
 
The Nasdaq Stock Market LLC
Rights included as part of the units, each entitling the holder to receive one-tenth of one Class A ordinary share, $0.0001 par value
 
GTERR
 
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
 
Emerging growth company
☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of November 17, 2026, there were 1,415,821 Class A ordinary shares, $0.0001 par value (excluding 788,534 Restricted Class A Shares, which are subject to vesting upon the consummation of an initial business combination), and 5,833,183 Class B ordinary shares, $0.0001 par value, issued and outstanding.



GLOBA TERRA ACQUISITION CORPORATION
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS

 
Page
Part I. Financial Information
 
Item 1. Interim Financial Statements
 
Condensed Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025
1
Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2026 and 2025
2
Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the three and nine months ended September 30, 2026 and 2025
3
Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2026 and 2025
4
Notes to Unaudited Condensed Financial Statements
5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
18
Item 3. Quantitative and Qualitative Disclosures About Market Risk
23
Item 4. Controls and Procedures
23
Part II. Other Information
 
Item 1. Legal Proceedings
24
Item 1A. Risk Factors
24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
26
Item 3. Defaults Upon Senior Securities
26
Item 4. Mine Safety Disclosures
27
Item 5. Other Information
27
Item 6. Exhibits
27
Signatures
28

i

Table of Contents
PART I - FINANCIAL INFORMATION

Item 1.
Interim Financial Statements.

GLOBA TERRA ACQUISITION CORPORATION
CONDENSED BALANCE SHEETS

   
September 30,
   
December 31,
 
   
2026
(Unaudited)
   
2025
 
ASSETS
           
Current Assets:
           
Cash
 
$
104,902
   
$
551,127
 
Prepaid expenses
   
157,197
     
139,441
 
Total Current Assets
   
262,099
     
690,568
 
Cash held in trust
   
183,101,959
     
178,380,953
 
Total Assets
 
$
183,364,058
   
$
179,071,521
 
LIABILITIES AND SHAREHOLDERS’ DEFICIT
               
Current Liabilities:
               
Accrued expenses
 
$
46,499
   
$
54,579
 
Accrued offering costs
   
30,002
     
40,692
 
Total Current Liabilities
   
76,501
     
95,271
 
Long-term Liabilities:
               
Accrued expenses
   
1,255,359
     
1,114,743
 
Total Liabilities
   
1,331,860
     
1,210,014
 
Commitments and contingencies (Note 6)
   
 
     
 
 
Class A ordinary shares, $0.0001 par value; 17,499,550 shares subject to possible redemption at $10.46 per share as of September 30, 2026 and $10.19 per share as of December 31, 2025
   
183,101,959
     
178,380,953
 
Shareholders’ Deficit:
               
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of September 30, 2026 and December 31, 2025
   
-
     
—
 
Class A ordinary shares, $0.0001 par value, 200,000,000 shares authorized, 394,267 issued and outstanding as of September 30, 2026 and December 31, 2025, excluding 17,499,550 shares subject to possible redemption
   
39
     
39
 
Class B ordinary shares, $0.0001 par value, 20,000,000 shares authorized, 5,833,183 shares issued and outstanding, as of September 30, 2026 and December 31, 2025
   
583
     
583
 
Additional paid-in capital
   
-
     
—
 
Accumulated deficit
   
(1,070,383
)
   
(520,068
)
Total Shareholders’ Deficit
   
(1,069,761
)
   
(519,446
)
Total Liabilities and Shareholders’ Deficit
 
$
183,364,058
   
$
179,071,521
 

The accompanying notes are an integral part of these unaudited condensed financial statements.

1

Table of Contents
GLOBA TERRA ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

   
For the Three
Months Ended
September 30, 2026
   
For the Three
Months Ended
September 30, 2025
   
For the Nine
Months Ended
September 30, 2026
   
For the
Nine
Months
Ended
September
30, 2025
 
Expenses
                       
Formation and operating expenses
 
$
137,119
   
$
355,907
   
$
550,315
   
$
355,907
 
TOTAL EXPENSES
   
(137,119
)
   
(355,907
)
   
(550,315
)
   
(355,907
)
                                 
OTHER INCOME
                               
Income earned on cash held in trust
   
1,613,349
     
1,668,159
     
4,721,006
     
1,668,159
 
TOTAL OTHER INCOME
   
1,613,349
     
1,668,159
     
4,721,006
     
1,668,159
 
                                 
Net Income
 
$
1,476,230
   
$
1,312,252
   
$
4,170,691
   
$
1,312,252
 
                                 
Weighted average of redeemable shares outstanding basic and diluted
   
17,499,550
     
16,143,335
     
17,499,550
     
5,460,246
 
Basic and diluted net income per ordinary share
 
$
0.09
   
$
0.09
   
$
0.25
   
$
0.27
 
Weighted average of non-redeemable shares outstanding basic and diluted
   
6,227,450
     
5,833,183
     
6,227,450
     
5,833,183
 
Basic and diluted net loss per ordinary share
 
$
(0.01
)
 
$
(0.02
)
 
$
(0.02
)
 
$
(0.03
)

The accompanying notes are an integral part of these unaudited condensed financial statements.

2

Table of Contents
GLOBA TERRA ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CHANGES IN
SHAREHOLDERS’ DEFICIT FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2026 AND 2025
(UNAUDITED)

 
Class A
Ordinary
Shares
   
Class B
Ordinary Shares



Additional
Paid-In
Capital


 
Accumulated
Deficit



Total Shareholders’
(Deficit)

   
Shares
   
Amount
   
Shares
   
Amount
Balance, December 31, 2025
   
394,267
   
$
39
     
5,833,183
   
$
583
   
$
—
   
$
(520,068
)
 
$
(519,446
)
Accretion of carrying value to redemption value
                           
—
     
—
     
(1,548,087
)
   
(1,548,087
)
Net income
                                           
1,340,806
     
1,340,806
 
Balance, March 31, 2026
   
394,267
   
$
39
     
5,833,183
   
$
583
   
$
—
   
$
(727,349
)
 
$
(726,727
)
Accretion of carrying value to redemption value
                           
—
     
—
     
(1,559,570
)
   
(1,559,570
)
Net income
                                           
1,353,655
     
1,353,655
 
Balance, June 30, 2026
   
394,267
     
39
     
5,833,183
     
583
     
—
     
(933,264
)
   
(932,642
)
 Accretion of carrying value to redemption value
                           
—
     
—
     
(1,613,349
)
   
(1,613,349
)
Net income
                                           
1,476,230
     
1,476,230
 
Balance, September 30, 2026
   
394,267
   
$
39
     
5,833,183
   
$
583
   
$
—
   
$
(1,070,383
)
 
$
(1,069,761
)

   
Class A
Ordinary
Shares
   
Class B
Ordinary Shares
     
Additional
Paid-In
Capital
     
Accumulated
Deficit
     
Total Shareholders’
Equity
  
   
Shares
   
Amount
   
Shares
   
Amount
Balance, December 31, 2024
   
-
   
$
-
     
5,833,183
   
$
583
   
$
24,417
   
$
-
   
$
25,000
 
Balance, March 31, 2025(1)(2)
   
-
   
$
-
     
5,833,183
   
$
583
   
$
24,417
   
$
-
   
$
25,000
 
Balance, June 30, 2025
   
-
   
$
-
     
5,833,183
   
$
583
   
$
24,417
   
$
-
   
$
25,000
 
Proceeds from private placement
   
394,267
     
39
     
—
     
—
     
3,154,097
     
—
     
3,154,136
 
Public warrants, fair value
   
—
     
—
     
—
     
—
     
3,581,926
     
—
     
3,581,926
 
Public rights, fair value
   
—
     
—
     
—
     
—
     
4,549,883
     
—
     
4,549,883
 
Offering costs allocated to private placement
   
—
     
—
     
—
     
—
     
(59,285
)
   
—
     
(59,285
)
Accretion of carrying value to redemption value
   
—
     
—
     
—
     
—
     
(11,251,038
)
   
(1,685,310
)
   
(12,936,348
)
Net income
   
—
     
—
     
—
     
—
     
—
     
1,312,252
     
1,312,252
 
Balance, September 30, 2025
   
394,267
   
$
39
     
5,833,183
   
$
583
   
$
—
   
$
(373,058
)
 
$
(372,436
)

(1)
Includes an aggregate of up to 760,850 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note 7).

(2)
Shares and associated accounts have been retroactively restated to reflect the surrender of 1,354,317 Class B ordinary shares to the Company for no consideration on March 25, 2025.

The accompanying notes are an integral part of these unaudited condensed financial statements.

3

Table of Contents
GLOBA TERRA ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)

   
For the Nine Months
Ended September 30, 2026
   
For the Nine Months
Ended September 30, 2025
 
Cash Flows from Operating Activities:
           
Net income
 
$
4,170,691
   
$
1,312,252
 
Income earned on cash held in trust
   
(4,721,006
)
   
(1,668,159
)
Changes in assets/liabilities to reconcile net income to net cash used in operating activities:
               
Prepaid expenses
   
(17,756
)
   
(137,249
)
Accrued expenses
   
132,536
     
236,613
 
Net Cash Used in Operating Activities
   
(435,535
)
   
(256,543
)
                 
Cash Flows from Investing Activities:
               
Proceeds from IPO deposited into trust
   
-
     
(174,995,500
)
Net Cash Used in Investing Activities
   
-
     
(174,995,500
)
                 
Cash Flows from Financing Activities:
               
Proceeds from issuance of Class A ordinary shares
   
-
     
174,995,500
 
Proceeds from private placement
   
-
     
3,154,136
 
Proceeds from promissory note – related party
   
-
      450,000  
Repayment of promissory note – related party
    -       (450,000
)
Payment of previously accrued offering costs
   
(10,690
)
   
(2,206,551
)
Net Cash (Used in) Provided by Financing Activities
   
(10,690
)
   
175,943,085
 
                 
Net change in cash
   
(446,225
)
   
691,042
 
Cash at beginning of period
   
551,127
     
-
 
Cash at end of period
 
$
104,902
   
$
691,042
 
                 
Supplemental Schedule of Non-Cash Financing Activities:
               
Accretion of Class A ordinary shares subject to possible redemption
 
$
4,721,006
   
$
1,668,159
 
Unpaid offering costs
 
$
—
   
$
989,114
 

The accompanying notes are an integral part of these unaudited condensed financial statements.

4

Table of Contents
GLOBA TERRA ACQUISITION CORPORATION
Notes to Unaudited Condensed Financial Statements

NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND GOING CONCERN

Globa Terra Acquisition Corporation (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 18, 2024. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”).

The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, however, it intends to focus its search on high potential businesses based in North America. The Company is an early-stage and emerging growth company; and, as such, the Company is subject to all of the risks associated with early-stage and emerging growth companies.

As of September 30, 2026, the Company had not commenced any operations. All activity for the period from October 18, 2024 (inception) through September 30, 2026 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below and subsequent to the Initial Public Offering related to the Business Combination. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.

Recent Developments

The Company was originally required to complete a Business Combination by October 9, 2026. The Company did not complete a Business Combination or fund either of the three-month extensions available under its amended and restated memorandum and articles of association by that date. On October 16, 2026, the Company received a Staff Delisting Determination from The Nasdaq Stock Market LLC (“Nasdaq”), which the Company has appealed by requesting a hearing before a Nasdaq Hearings Panel (see Notes 6 and 11). On November 9, 2026, the Company held an extraordinary general meeting of shareholders (the “Shareholder Meeting”) at which its shareholders approved, by special resolution, amendments to its amended and restated memorandum and articles of association (the “Extension Amendment”) to extend the date by which the Company must complete a Business Combination from October 9, 2026 to July 9, 2027, consisting of an initial one-month extension to November 9, 2026, followed by up to eight additional one-month extensions at the sole discretion of the Company’s Board of Directors (the “Extension Proposal”). The Company filed the Extension Amendment with the Registrar of Companies of the Cayman Islands on November 10, 2026, effective November 9, 2026. In November 2026, extension payments of $524,987 and $40,862 were deposited into the Trust Account, extending the date by which the Company must complete a Business Combination to December 9, 2026 (see Note 11). In connection with the Extension Proposal, holders of 16,477,996 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account, leaving 1,021,554 Public Shares outstanding.

On November 8, 2026, the Company entered into a business combination agreement (the “Business Combination Agreement”) with Nature’s Ledger Inc., a corporation existing under the Business Corporations Act (Alberta) (“Nature’s Ledger”) (see Note 11).

There can be no assurance that the monthly extension contributions will be funded, that the Company’s Nasdaq appeal will be successful, or that the Company will complete the proposed business combination with Nature’s Ledger or any other Business Combination.
 
On July 10, 2025, the Company consummated its Initial Public Offering of 17,499,550 units, including the full exercise of the over-allotment option for 2,282,550 units (the “Units” and, with respect to the Class A ordinary shares (as defined below) included in the Units offered, the “Public Shares”) at $10.00 per Unit, generating gross proceeds to the Company of $174,995,500 (the “Public Proceeds”).

Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of (i) 394,267 private placement units (the “Private Placement Units”) and (ii) 788,534 Class A ordinary shares, which shares would vest only upon the consummation of the initial Business Combination (each, a “Restricted Class A Share” and the Restricted Class A Shares collectively with the Private Placement Units, the “Private Placement Securities”) to Globa Terra Management LLC (the “Sponsor”) and one institutional investor (the “Private Placement Investor”) for an aggregate purchase price of $3,154,136 in private placements (the “Private Placements”). For each $10.00 invested in the Private Placements, the applicable investor will receive (i) one and one-fourth Private Placement Units and (ii) two and one- half Restricted Class A Shares.

Transaction costs amounted to $3,195,665, consisting of $750,000 of cash underwriting fee and $2,445,665 of other offering costs.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the private placement securities, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding taxes payable on the interest income earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination. Management has agreed that $10.00 per Unit sold in the Initial Public Offering, including proceeds of the sale of the private placement securities, will be held in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 of the Investment Company Act, or in an interest-bearing demand deposit account at a U.S.-chartered bank, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.

5

Table of Contents
The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest then in the Trust Account). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants or Rights. The Public Shares subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

The Company will not redeem Public Shares in an amount that would cause its net tangible assets to be less than any net tangible asset or cash requirement that may be contained in the agreement relating to the Business Combination. If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination only if the Company receives approval by way of an ordinary resolution under Cayman Islands law approving a Business Combination, which requires a resolution be passed by a majority of the holders of the Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) and the Class B ordinary shares, par value $0.0001 (the “Class B ordinary shares,” and together with the Class A ordinary shares, the “ordinary shares”) as, being entitled to do so, vote in person or by proxy at a general meeting of the Company, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (as amended, the “Articles”), conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem its Public Shares without voting and, if it does vote, irrespective of whether it votes for or against a proposed Business Combination. The Sponsor has agreed to waive its redemption rights with respect to any such shares in connection with a shareholder vote to approve a Business Combination.

Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Articles provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.

The Sponsor has agreed (a) to waive its redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and (b) not to propose an amendment to the Articles (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial Business Combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment.

If the Company has not completed a Business Combination within the timeframe specified within the Articles (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants or Rights, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.
 
The Company did not deposit funds into the Trust Account to effect either three-month extension and did not complete a Business Combination within the initial Combination Period, which ended on October 9, 2026. On November 9, 2026, the Company’s shareholders approved the Extension Proposal, and, following the deposit of the two extension payments described in Note 11, the Combination Period currently runs through December 9, 2026. The Board of Directors may further extend the Combination Period on a monthly basis up to July 9, 2027, subject to the deposit of the required extension contribution into the Trust Account for each such extension. See “Going Concern Considerations” below and Notes 6 and 11.
 
The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to the Founder Shares it will receive if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or any of its respective affiliates acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

6

Table of Contents
In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations, and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the Trust Account, the funds available for the Company’s initial Business Combination and redemptions could be reduced to less than $10.00 per Public Share. In such event, the Company may not be able to complete its initial Business Combination, and the Public Shareholders would receive such lesser amount per share in connection with any redemption of their Public Shares. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

Going Concern Considerations

In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Subtopic 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that the Company did not complete a Business Combination by October 9, 2026, the original deadline under the Articles, and on October 16, 2026, received a Staff Delisting Determination from Nasdaq, which the Company has appealed by requesting a hearing before a Nasdaq Hearings Panel (see Notes 6 and 11). Although the Company’s shareholders approved the Extension Proposal on November 9, 2026, and extension payments deposited into the Trust Account in November 2026 extended the Company’s deadline to complete a Business Combination to December 9, 2026, the Company’s ability to extend the Combination Period beyond each monthly deadline, up to July 9, 2027, depends on the deposit of the required extension contributions into the Trust Account, and there can be no assurance that such contributions will be made, that the Company’s Nasdaq appeal will be successful, or that the Company will complete its proposed business combination with Nature’s Ledger or any other Business Combination by July 9, 2027. In addition, as of September 30, 2026, the Company had $104,902 of cash held outside the Trust Account, working capital of $185,598, and $1,255,359 of deferred obligations to service providers. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed financial statements are issued, and management’s plans do not alleviate that substantial doubt. The unaudited condensed financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Risks and Uncertainties

Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, including rising trade tensions between the United States and China, the U.S. federal government shutdown, and other uncertainties regarding actual and potential shifts in the U.S. and foreign, trade, economic and other policies with other countries, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics), may contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Specifically, the rising conflict between Russia and Ukraine, and the rising conflicts in the Middle East, and resulting market volatility could adversely affect the Company’s ability to complete a Business Combination. In response to the conflict between Russia and Ukraine, the U.S. and other countries have imposed sanctions or other restrictive actions against Russia. Any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on the Company’s ability to complete a Business Combination and the value of the Company’s securities. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

7

Table of Contents
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The interim results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any future periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Related Parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation (“FDIC”) limit and cash held in the trust with a financial institution, which, at times, may exceed the FDIC limit. As of September 30, 2026 and December 31, 2025, the cash held in excess of the FDIC limit was $0 and $301,127, respectively. As of September 30, 2026 and December 31, 2025, the cash held in the trust in excess of the FDIC limit was $182,851,959 and $178,130,953, respectively. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

8

Table of Contents
Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2026 and December 31, 2025.

Offering Costs

The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering” and Topic 5T – “Accounting for Expenses or Liabilities Paid by Principal Stockholder(s).”

Deferred offering costs consist of costs incurred in connection with preparation for the Initial Public Offering, which include professional and registration fees incurred. Deferred offering costs, together with the underwriting discounts and commissions, were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. As of September 30, 2026 and December 31, 2025, the Company had deferred offering costs of $0.

Certain service providers have agreed to defer the payment of certain fees and expenses until the completion of the Initial Business Combination. The amounts as of September 30, 2026, and December 31, 2025 were $1,255,359 and $1,114,743, respectively.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the unaudited condensed financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2026, and December 31, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements.

Net Income (Loss) per Ordinary Share

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company applies the two-class method. Income earned on the Trust Account is allocated to the Class A ordinary shares subject to possible redemption, and formation and operating expenses are allocated between the redeemable shares and the non-redeemable Class A and Class B ordinary shares pro rata based on weighted average shares outstanding. Net income (loss) per share for each class is computed by dividing the income (loss) allocated to that class by its weighted average shares outstanding. The 788,534 Restricted Class A Shares, which vest only upon the consummation of a Business Combination, are excluded from weighted average shares outstanding until they vest. Accretion associated with the redeemable Ordinary Shares is excluded from income per Ordinary Share as the redemption value approximates fair value. The calculation of diluted income per Ordinary Share does not consider the effect of the Rights and Warrants issued in connection with the Initial Public Offering and Private Placement since their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share.

   
Three Months Ended
September 30, 2026
   
Three Months Ended
September 30, 2025
 
       
Redeemable
     
Non-
Redeemable
       
Redeemable
     
Non-
Redeemable
  
Basic and diluted net income (loss) per ordinary share numerator:
                       
Interest income
 
$
1,613,349
   
$
-
   
$
1,668,159
   
$
-
 
Less: Allocation of expenses
   
(101,130
)
   
(35,989
)
   
(261,439
)
   
(94,468
)
Total
 
$
1,512,219
   
$
(35,989
)
 
$
1,406,720
   
$
(94,468
)
                   
Basic and diluted net income (loss) per ordinary share denominator:
                 
Weighted-average shares outstanding
   
17,499,550
     
6,227,450
     
16,143,335
     
5,833,183
 
Basic and diluted net income (loss) per ordinary share
 
$
0.09
   
$
(0.01
)
   
0.09
     
(0.02
)

   
Nine Months Ended
September 30, 2026
   
Nine Months Ended
September 30, 2025
 
       
Redeemable
     
Non-
Redeemable
       
Redeemable
     
Non-
Redeemable
  
Basic and diluted net income (loss) per ordinary share numerator:
                       
Interest income
 
$
4,721,006
   
$
-
   
$
1,668,159
   
$
-
 
Less: Allocation of expenses
   
(405,878
)
   
(144,437
)
   
(172,077
)
   
(183,830
)
Total
 
$
4,315,128
   
$
(144,437
)
 
$
1,496,082
   
$
(183,830
)
                   
Basic and diluted net income (loss) per ordinary share denominator:
                 
Weighted-average shares outstanding
   
17,499,550
     
6,227,450
     
5,460,246
     
5,833,183
 
Basic and diluted net income (loss) per ordinary share
 
$
0.25
   
$
(0.02
)
   
0.27
     
(0.03
)

Cash Held in Trust Account

As of September 30, 2026 and December 31, 2025, the Company had $183,101,959 and $178,380,953, respectively, in cash held in the Trust Account. The fair value of the cash held in trust is measured under Level 1 in the fair value hierarchy.

9

Table of Contents
Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the unaudited condensed balance sheets, primarily due to their short-term nature.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

•
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
•
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
•
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the unaudited condensed balance sheet date.

Warrant Instruments

The Company accounts for the Public Warrants issued in connection with the Initial Public Offering and the private placement warrants included in the Private Placement Units in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging.” Under ASC 815-40, the Public Warrants (as defined below) and the private placement warrants meet the criteria for equity treatment and as such were recorded in shareholders’ equity. If the Public Warrants and private placement warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the unaudited condensed statements of operations.

Rights

The Company accounts for the Rights issued in connection with the Initial Public Offering and the private placement rights included in the Private Placement Units in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging.” Under ASC 815-40, the Rights (as defined below) and the private placement rights meet the criteria for equity treatment and as such were recorded in shareholders’ equity. If the Rights and private placement rights no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the unaudited condensed statements of operations.

Class A Ordinary Shares Subject to Redemption

The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies the Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available) and accumulated deficit. Accordingly, as of September 30, 2026 and December 31, 2025, Class A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s unaudited condensed balance sheet.

10

Table of Contents
As of September 30, 2026 the Class A ordinary shares subject to redemption reflected in the unaudited condensed balance sheet are reconciled in the following table:

Gross proceeds
 
$
174,995,500
 
Less: Proceeds allocated to public warrants
   
(3,581,926
)
Less: Proceeds allocated to public rights
   
(4,549,883
)
Less: Offering costs allocated to public shares
   
(3,136,380
)
Add: Accretion of carrying value to redemption value
   
14,653,642
 
Class A ordinary shares subject to possible redemption December 31, 2025
   
178,380,953
 
Add: Accretion of carrying value to redemption value
   
1,548,087
 
Class A ordinary shares subject to possible redemption March 31, 2026
   
179,929,040
 
Add: Accretion of carrying value to redemption value
   
1,559,570
 
Class A ordinary shares subject to possible redemption June 30, 2026
   
181,488,610
 
Add: Accretion of carrying value to redemption value
   
1,613,349
 
Class A ordinary shares subject to possible redemption September 30, 2026
 
$
183,101,959
 

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.

NOTE 3 — INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 17,499,550 Units (including the full exercise of the over-allotment option for 2,282,550 units) at a purchase price of $10.00 per Unit. Each Unit consists of one Class A ordinary share, three-fourths of one redeemable warrant (“Public Warrant”) and one Right entitling the holder to receive one-tenth (1/10) of one Class A share, so the holder must hold Rights in multiples of 10 in order to receive shares for all of their Rights upon closing of a Business Combination (“Right”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8).

NOTE 4 — PRIVATE PLACEMENTS

Simultaneously with the closing of the Initial Public Offering the Sponsor and the Private Placement Investor purchased an aggregate of (i) 394,267 Private Placement Units and (ii) 788,534 Restricted Class A Shares, which shares would vest only upon the consummation of the initial Business Combination, at a combined price of $10.00 per Private Placement Security for an aggregate of $3,154,136 (whether or not the underwriters’ over-allotment option is exercised). The Sponsor purchased 285,413 private placement securities, consisting of (a) 356,767 Private Placement Units and (b) 713,534 restricted Class A shares, for an aggregate purchase price of $2,854,136. The Private Placement Investor purchased directly from the Company an aggregate of 30,000 Private Placement Securities, consisting of (a) 37,500 Private Placement Units and (b) 75,000 restricted Class A shares, for an aggregate purchase price of $300,000. The proceeds from the Private Placements were used to pay underwriting commissions and offering costs and to fund working capital; the Trust Account was funded with $174,995,500, or $10.00 per Public Share. If the Company does not complete a Business Combination within the Combination Period, the funds held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), the Founder Shares (as defined below) and private placement shares will not be entitled to liquidating distributions from the Trust Account, the private placement warrants and private placement rights will expire worthless and the Restricted Class A Shares will not vest. The Private Placement Units (including the private placement shares, the private placement warrants, the Class A ordinary shares issuable upon exercise of the private placement warrants, the private placement rights, and the Class A ordinary shares issuable upon exercise of the private placement rights) will not be transferable, assignable or salable until 180 days after the completion of an initial Business Combination and the Restricted Class A Shares will not be transferable, assignable or salable until 90 days after the completion of an initial Business Combination, subject to certain exceptions.

Certain institutional investors (none of which are affiliated with any member of management, the Sponsor or any other investor), purchased non-managing membership interests in the Sponsor reflecting interests in an aggregate of (i) 212,500 of the 356,767 private placement units purchased by the Sponsor and (ii) 425,000 of the 713,534 restricted Class A shares purchased by the Sponsor, at a price of $10.00 per interest in each private placement security ($1,700,000 in the aggregate), in private placements that closed simultaneously with the closing of the Initial Public Offering. Subject to each Sponsor non-managing member purchasing interest in the Sponsor representing the private placement securities allocated to it in connection with the closing of the Initial Public Offering, the Sponsor issued non-managing membership interests at a nominal purchase price to the Sponsor non-managing member reflecting interests in an aggregate of 1,700,000 founder shares.

Each Private Placement Unit consists of one private Class A ordinary share, three-fourths of one private placement warrant, and one private placement right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination.

In connection with the Private Placement, the Sponsor sold 300,000 Founder Shares that were owned by the Sponsor to the Private Placement Investor for $1,500. The estimated fair value of these shares is $360,000.

11

Table of Contents
NOTE 5 — RELATED PARTIES

Founder Shares

On October 18, 2024, the Sponsor received 7,187,500 of the Company’s Class B ordinary shares (the “Founder Shares”) in exchange for a payment of $25,000 to a vendor. On March 25, 2025, the Sponsor surrendered 1,354,317 Founder Shares for no consideration and thereafter held 5,833,183 Founder Shares. Shares and associated accounts have been retroactively restated to reflect the surrender of 1,354,317 Class B ordinary shares to the Company for no consideration on March 25, 2025.

Up to 760,850 Founder Shares are subject to forfeiture by the holders thereof depending on the extent to which the underwriter’s over-allotment option is exercised, so that the number of Founder Shares will collectively represent 25% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering. No Class B ordinary shares were forfeited as the underwriters fully exercised the over-allotment option.

On May 14, 2025 and June 11, 2025, the Sponsor transferred an aggregate of 418,188 of its Founder Shares to the Company’s independent directors and certain members of the Company’s management team for their services. The estimated fair value of these shares is $501,826. On May 30, 2025, the Sponsor transferred an additional 87,500 of its Founder Shares to Meridien Peak as consideration for consulting services. The estimated fair value of these shares is $105,000. The fair value of shares will be recognized as an expense when the initial business combination is probable. As of September 30, 2026, no compensation expense had been recognized for these shares.

The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $11.50 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.

General and Administrative Services

The Company entered into an agreement, commencing on the effective date of the Initial Public Offering through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor or an affiliate thereof a monthly fee of $15,000 for office space, administrative and shared personnel support services. For the three months ended September 30, 2026 and 2025, the Company incurred expenses of $45,000 and $40,000, respectively, related to this agreement. For the nine months ended September 30, 2026 and 2025, the Company incurred expenses of $135,000 and $40,000, respectively. As of September 30, 2026 and December 31, 2025, there was $0 owed to the Sponsor for this agreement.

Related Party Notes

On April 16, 2025 and June 12, 2025, the Company entered into notes payable with the Sponsor for $300,000 and $450,000, respectively. The notes were non-interest bearing with a maturity date that is the earlier of December 31, 2025 or the date the Company completes an Initial Public Offering. As of the date of the Initial Public Offering, the Company had $450,000 outstanding on these notes, which was deemed repaid in connection with the Private Placement.
 
Working Capital Loans
 
In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Up to $2,500,000 of such Working Capital Loans may be convertible into private placement units at a price of $10.00 per unit at the option of the lender. As of September 30, 2026 and December 31, 2025, no Working Capital Loans were outstanding.
 
Extension Promissory Note

In November 2026, the Company issued a non-interest-bearing promissory note to the Sponsor to evidence the Sponsor’s commitment to fund up to $250,000 in connection with the extension of the Combination Period, of which $100,000 had been funded as of November 12, 2026. The note is repayable upon the closing of the Proposed Business Combination. The Sponsor is also a party to the promissory note issued by the Company to Nature’s Ledger, under which the Sponsor has agreed, among other things, to vote its ordinary shares in favor of the issuance of shares upon conversion of that note and to waive any adjustment to the conversion ratio of the Class B ordinary shares resulting from that issuance. See Note 11.
 
Consulting Agreements

The Sponsor is supported by affiliates of Meteora Capital, LLC (“Meteora”) and Meridien Peak, (“Meridien Peak” and together with Meteora, the “Advisors”).

Meteora acts as an advisor to the Company and the Sponsor pursuant to a consulting agreement. In connection with the Initial Public Offering and Private Placement, the Company incurred issuance costs of $150,000, all of which was paid from the proceeds of the Private Placements.

Meridien Peak also acts as an advisor to the Company and the Sponsor pursuant to a consulting agreement entered into by Meridien Peak and the Sponsor. In connection with the Initial Public Offering and Private Placement, the Company incurred issuance costs of $462,925. In addition to these amounts, the Sponsor also transferred 87,500 Founder Shares to Meridien Peak on May 30, 2025. These shares have an estimated fair value of $105,000. The fair value of the shares will be recognized as an expense when the initial business combination is probable.

12

Table of Contents
NOTE 6 — COMMITMENTS AND CONTINGENCIES

Registration Rights

The holders of the (i) Founder Shares, (ii) the Class A ordinary shares included in the Private Placement Units, Private Placement Warrants included in the Private Placement Units, and the Class A ordinary shares issuable upon exercise of such Private Placement Warrants, the Private Placement Rights and the Class A ordinary shares issuable upon exercise of such Private Placement Rights; (iii) Restricted Class A Shares, and (iv) any Private Placement Units that may be issued upon conversion of Working Capital Loans and their permitted transferees will be entitled to registration rights pursuant to a registration rights agreement signed on the effective date of Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriter a 45-day option from the date of the Initial Public Offering to purchase 2,282,550 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The underwriter fully exercised the over-allotment option on July 9, 2025.

The underwriter received a cash underwriting commission of $750,000, paid upon the closing of the Initial Public Offering.
 
Nasdaq Delisting Determination
 
On October 16, 2026, the Company received a letter from Nasdaq (the “Staff Determination”) notifying the Company that it had not completed a business combination within the timeframe required by Nasdaq IM-5101-2(b) and that Nasdaq had initiated procedures to delist the Company’s securities. The Staff Determination stated that the Company could request a hearing before a Nasdaq Hearings Panel (the “Panel”) by 4:00 p.m. Eastern Time on October 23, 2026 and that, absent a timely request, trading in the Company’s securities would be suspended at the opening of business on October 27, 2026. The Company requested a hearing before the Panel, which stays the suspension of the Company’s securities pending the Panel’s decision (see Note 11). There can be no assurance that the Panel will grant the Company’s request for continued listing.

Trust Agreement and Redemption Obligations
 
Under the Articles and the Investment Management Trust Agreement dated July 8, 2025 between the Company and Odyssey Transfer and Trust Company, if the Company did not complete a Business Combination within the Combination Period, the Company was required to redeem 100% of the Public Shares and the Trust Account was to be liquidated. Following the expiration of the Combination Period on October 9, 2026 and until the Company’s shareholders approved the Extension Proposal on November 9, 2026, the Company had not redeemed the Public Shares or liquidated the Trust Account and was not in compliance with these provisions. As a result, the Company could be subject to claims by Public Shareholders, the trustee or others. As of November 17, 2026, the Company is not aware of any such claims.
 
NOTE 7 — SHAREHOLDERS’ DEFICIT

Preference Shares — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2026 and December 31, 2025 there were no preference shares issued or outstanding.

Class A Ordinary Shares — The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one vote for each share. As of September 30, 2026 and December 31, 2025, there were 394,267 Class A ordinary shares issued and outstanding (excluding the 17,499,550 shares subject to possible redemption). In addition, 788,534 Restricted Class A Shares were issued and are outstanding but are subject to vesting upon the consummation of a Business Combination and are excluded from the shares presented above.

Class B Ordinary Shares — The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders of Class B ordinary shares are entitled to one vote for each share. As of September 30, 2026 and December 31, 2025, there were 5,833,183 Class B ordinary shares issued and outstanding. No Class B ordinary shares were forfeited, as the underwriter exercised the over-allotment option in full on July 9, 2025. Only holders of the Class B ordinary shares will have the right to vote on the appointment of directors prior to the Business Combination. Holders of ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as otherwise required by law.

In connection with its initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of the Initial Public Offering.

The Founder Shares are designated as Class B ordinary shares and will automatically convert at a ratio of one-for-one into Class A ordinary shares (which such Class A ordinary shares issued upon conversion will not have redemption rights or be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at the time of the initial Business Combination, or earlier at the option of the holder. The conversion ratio is subject to adjustment so that the Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, 25% of the total ordinary shares outstanding after the Initial Public Offering, subject to certain exclusions, as provided in the Articles.

Rights — Each Right entitles the holder to receive one-tenth (1/10) of one Class A ordinary share upon the consummation of the initial Business Combination. No fractional shares will be issued upon conversion of the Rights. As of September 30, 2026 and December 31, 2025, there were 17,893,817 Rights outstanding (17,499,550 Public Rights and 394,267 private placement rights), entitling the holders to receive an aggregate of 1,789,381 Class A ordinary shares upon the consummation of a Business Combination. If the Company does not complete a Business Combination, the Rights will expire worthless.
 
NOTE 8 — WARRANTS

There were 13,420,363 warrants outstanding (13,124,663 Public Warrants and 295,700 private placement warrants) as of September 30, 2026 and December 31, 2025. Public Warrants may only be exercised for a whole number of shares. Commencing on July 25, 2025, holders of the Units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares, Public Warrants and Rights to receive one-tenth of one Class A ordinary share included in the Units. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months after the effective date of the registration statement relating to the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

13

Table of Contents
The Company will not be obligated to issue any Class A ordinary share pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Redemption of Warrants When the Price per Class A ordinary share Equals or Exceeds $18.00 — Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants:

•
in whole and not in part;
•
at a price of $0.01 per Public Warrant;
•
upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and
•
if, and only if, the last reported sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share splits, share dividends, reorganization, recapitalizations and the like) for any 10 trading days within a 20-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to warrant holders.

If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

If the Company calls the Public Warrants for redemption as described in this paragraph, its management will have the option to require any holder that wishes to exercise their warrant following the notice of redemption to do so on a cashless basis. In the case of such a cashless exercise, each holder would pay the exercise price by surrendering the Public Warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” less the exercise price of the warrants by (y) the fair market value. The “fair market value” as used in the preceding sentence shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of redemption is sent to the holders of the public warrants. If its management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of Class A ordinary shares to be received upon exercise of the warrants, including the “fair market value” in such case.

The Company has established the $18.00 per share (as adjusted) redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the public warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the Public Warrants, each Public Warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $18.00 redemption trigger price, as well as the $11.50 Public Warrant exercise price after the redemption notice is issued.

In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by its board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the initial shareholders prior to such issuance) (the “Newly Issued Price”),

(y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of its initial Business Combination on the date of the completion of its initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 20 day trading period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.

14

Table of Contents
The private placement warrants included in the Private Placement Units are identical to the Public Warrants underlying the Units being sold in the Initial Public Offering, except that the private placement warrants and the Class A ordinary shares issuable upon the exercise of the private placement warrants will not be transferable, assignable or saleable until 180 days after the completion of a Business Combination, subject to certain limited exceptions.

NOTE 9 — SEGMENT INFORMATION

ASC Topic 280, Segment Reporting, establishes standards for companies to report, in their unaudited condensed financial statements, information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.

The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company has one operating segment and one reportable segment.

The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the unaudited condensed statement of operations as net income or loss. The measure of segment assets is reported on the unaudited condensed balance sheet as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets.

Formation and operating expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination or similar transaction within the business combination period. The CODM also reviews formation and operating expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. Formation and operating expenses, as reported on the unaudited condensed statement of operations, are the significant segment expenses provided to the CODM on a regular basis.

   
As of
September 30,
2026
 
Cash
 
$
104,902
 
Prepaid expenses
   
157,197
 
Cash held in trust
   
183,101,959
 
Total Assets
 
$
183,364,058
 

NOTE 10 — FAIR VALUE MEASUREMENTS

The fair value of the $183,101,959 cash held in trust is measured under Level 1 in the fair value hierarchy.

The fair value of the Public and Private Warrants is measured under Level 3 in the fair value hierarchy as of July 10, 2025. The fair value of Public Warrants was determined using Black-Scholes Model. The expected term of the warrant is based on the actual term of the warrant in the event of a successful business combination. The probability of an initial business combination is based on historical data from SPACs that have successfully completed an initial public offering followed by a business combination. The volatility is based on historical volatility of comparable publicly traded SPACs.

The Public Warrants have been classified within shareholders’ equity and will not require remeasurement after issuance. The market assumptions used to determine fair value as follows:

   
As of
July 10,
2025
 
Term
 
5 years
 
Dividends
 
$
0
 
Risk Free Rate
   
3.93
%
Probability of an Initial Business Combination
   
26.00
%
Volatility
   
5.00
%

The fair value of the Public and Private Rights is measured under Level 3 in the fair value hierarchy as of July 10, 2025. The fair value of Public Rights was determined using Black-Scholes Model. The expected term of the right is based on the actual term of the right in the event of a successful business combination. The probability of an initial business combination is based on historical data from SPACs that have successfully completed an initial public offering followed by a business combination. The volatility is based on historical volatility of comparable publicly traded SPACs.

15

Table of Contents
The Public Rights have been classified within shareholders’ equity and will not require remeasurement after issuance.

The market assumptions used to determine fair value as follows:

   
As of
July 10, 2025
 
Market adjustment (1)
   
26.00
%

(1) Includes probability of an Initial Business Combination and other factors

NOTE 11 — SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the unaudited condensed balance sheet date through the date that the unaudited condensed financial statements were available to be issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.
 
Expiration of the Combination Period
 
The Company did not complete a Business Combination by October 9, 2026 and did not deposit funds into the Trust Account to effect either three-month extension available under the Articles. See Notes 1 and 6.
 
Extension Meeting and Extension Amendment
 
On October 9, 2026, the Company filed a preliminary proxy statement with the SEC, which it amended on October 13, 2026, and on October 26, 2026, the Company filed a definitive proxy statement for an extraordinary general meeting of shareholders to approve the Extension Proposal. The Company’s shareholders approved the Extension Proposal by special resolution. On November 10, 2026, the Company filed the Extension Amendment with the Registrar of Companies of the Cayman Islands, effective November 9, 2026.

Under the Extension Amendment, the Combination Period was extended by one month, from October 9, 2026 to November 9, 2026 (the “Initial Extension”), subject to the deposit into the Trust Account of $0.03 per Public Share in issue as of the date of the Shareholder Meeting (the “Initial Extension Payment”) within two business days following the Shareholder Meeting and prior to the redemption of any Public Shares in connection with the Extension Proposal. Following the Initial Extension, the Board of Directors may, without a shareholder vote, elect to further extend the Combination Period up to eight times, by one additional month each time, up to July 9, 2027, by depositing into the Trust Account, for each such month, the lesser of (x) $0.04 per non-redeemed Public Share and (y) $50,000.

Extension Payments

Following the approval of the Extension Proposal, the following extension payments were deposited into the Trust Account in November 2026: (i) on November 10, 2026, the Initial Extension Payment of $524,987, representing $0.03 per Public Share for each of the 17,499,550 Public Shares outstanding as of the date of the Shareholder Meeting, which extended the Combination Period from October 9, 2026 to November 9, 2026; and (ii) on November 10, 2026, a monthly extension contribution of $40,862, representing the lesser of $0.04 per non-redeemed Public Share and $50,000, which extended the Combination Period from November 9, 2026 to December 9, 2026. The extension payments were funded by the Sponsor and Nature’s Ledger with the proceeds of the extension funding described under “Extension Funding” below.

In connection with the Extension Proposal, holders of 16,477,996 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account of approximately $10.54 per share, or approximately $173,652,702 in the aggregate, leaving 1,021,554 Public Shares outstanding and approximately $10,765,617 in the Trust Account.

Business Combination Agreement

On November 8, 2026, the Company entered into the Business Combination Agreement with Nature’s Ledger. Pursuant to the Business Combination Agreement, 1587815 B.C. Ltd., a company existing under the laws of British Columbia (“BCCo”), is expected to become a party to the Business Combination Agreement by executing a joinder; the Business Combination Agreement is binding on the Company and Nature’s Ledger whether or not BCCo does so. Nature’s Ledger is engaged in the origination, development, verification, aggregation, registration, marketing and sale of carbon credits and environmental attributes and related services. Pursuant to the Business Combination Agreement, and subject to the terms and conditions set forth therein, among other things, (i) the Company will merge with and into a Cayman Islands exempted company to be incorporated as a wholly-owned subsidiary of the Company (“Pubco”), with Pubco surviving (the “SPAC Merger”), (ii) Pubco will continue from the Cayman Islands to Alberta (the “Continuance”), and (iii) pursuant to a plan of arrangement under the Business Corporations Act (Alberta) (the “Arrangement”), Nature’s Ledger, BCCo and a newly formed Alberta subsidiary of the Company will amalgamate to form a corporation that will continue as a wholly-owned subsidiary of Pubco (collectively, the “Proposed Business Combination”). Pubco will be the publicly traded parent company following the Proposed Business Combination.

Immediately prior to the SPAC Merger, each Class B ordinary share will first convert into one Class A ordinary share, and at the effective time of the SPAC Merger, each Class A ordinary share then outstanding (other than redeemed, cancelled or dissenting shares) will convert into one common share of Pubco (“Pubco Common Share”). Each of the Company’s warrants will become a warrant to acquire Pubco Common Shares, and each of the Company’s rights will become a right to receive one-tenth of one Pubco Common Share. Securityholders of Nature’s Ledger and BCCo will receive Pubco Common Shares and replacement warrants, as applicable, based on a pre-money equity value of Nature’s Ledger of $323,775,000 (subject to adjustment as provided in the Business Combination Agreement), a pre-money equity value of BCCo of $825,000, and a value of $10.00 per Pubco Common Share. Pre-closing holders of Nature’s Ledger Class A shares and Class G preferred shares may also receive up to 6,557,772 additional Pubco Common Shares as earnout consideration, subject to the achievement of specified share price or EBITDA milestones over the five years following closing. In connection with the Proposed Business Combination, Nature’s Ledger will use its reasonable best efforts to raise $10,000,000 in a private placement of subscription receipts (the “PIPE Financing”), with each PIPE investor to receive one Pubco Common Share for each $10.00 subscribed. To facilitate the PIPE Financing, (i) the Sponsor will forfeit up to 500,000 of its Founder Shares (the “Sponsor PIPE Facilitation Shares”), and (ii) the Pubco Common Shares allocable to the PIPE investors will be increased by up to 3,000,000 shares plus a number of shares equal to the Sponsor PIPE Facilitation Shares, in each case as mutually and reasonably determined by the Sponsor and Nature’s Ledger.

16

Table of Contents
The Business Combination Agreement contains customary representations, warranties and covenants and requires Nature’s Ledger and BCCo (the “Company Parties”) to deliver PCAOB-audited financial statements by December 31, 2026. The closing of the Proposed Business Combination is subject to customary closing conditions, including, among others, approval of the Company’s shareholders (including of an amendment to the Articles providing for the redemption of Public Shares following such approval but prior to the SPAC Merger) and of the shareholders of Nature’s Ledger and BCCo, approval of the Arrangement by the Court of King’s Bench of Alberta, the effectiveness of a registration statement on Form F-4 or Form S-4, and approval of the listing of the Pubco Common Shares on Nasdaq. The Business Combination Agreement may be terminated under certain circumstances, including by either the Company or the Company Parties if the closing has not occurred by July 9, 2027 (which date may be extended, but not beyond the end of the Combination Period), and by the Company if the PCAOB-audited financial statements of the Company Parties are not delivered by January 31, 2027. In certain circumstances, a terminating party is entitled to reimbursement of its documented out-of-pocket transaction expenses, which, in the case of the Company, are payable only from funds held outside the Trust Account. Concurrently with the execution of the Business Combination Agreement, the Company, the Sponsor, Nature’s Ledger and certain other shareholders of the Company entered into a sponsor support agreement, and the Company, Nature’s Ledger and certain shareholders of Nature’s Ledger entered into a company support agreement.

Extension Funding

Pursuant to the Business Combination Agreement, the Sponsor and Nature’s Ledger have agreed to fund $250,000 and $750,000, respectively, in connection with the extension of the Combination Period, evidenced by promissory notes issued by the Company (see Note 5 and “Nature’s Ledger Promissory Note” below). As of November 12, 2026, the Sponsor had funded $100,000 and Nature’s Ledger had funded $500,000 of these amounts, a portion of which was used to fund the extension payments described under “Extension Payments” above.
 
Nature’s Ledger Promissory Note
 
The Company issued an unsecured promissory note, dated as of October 9, 2026, to Nature’s Ledger in a principal amount of up to $750,000 (the “NL Note”). The Sponsor is also a party to the NL Note for certain purposes. Under the NL Note, Nature’s Ledger agreed to advance $500,000 to the Company (the “Initial Advance”), to be used to fund the deposits into the Trust Account required to extend the Combination Period, and the remaining $250,000 within five business days after the Company and Nature’s Ledger entered into a definitive business combination agreement (the “Second Advance”), to be used solely to fund extension deposits or to pay expenses relating to the business combination with Nature’s Ledger. On October 9, 2026, $500,000 had been advanced under the NL Note, and on November 9, 2026,  Nature's Ledger advanced the remaining $250,000.
 
The NL Note is payable on the earlier of the date on which the Company consummates its initial Business Combination and the date on which the winding up of the Company becomes effective. Simple interest accrues on each advance from the date it is made at a rate of 8.00% per annum on amounts repaid in cash and 12.00% per annum on amounts converted into shares as described below. Nature’s Ledger has waived any claim against the Trust Account, except that, upon the consummation of the Business Combination, the Company is required to repay any unconverted principal and accrued interest out of the proceeds released to it from the Trust Account, if any, after payment to holders of the Public Shares
 
At any time before the closing of the Business Combination, Nature’s Ledger may elect to convert all, but not less than all, of the unpaid principal of and accrued interest on the NL Note, effective immediately prior to the closing, into Class A ordinary shares of the Company (or the corresponding listed common shares of its successor) at a conversion price equal to the lower of (i) $5.00 per share and (ii) the lowest effective price paid by any investor in a qualifying equity or equity-linked financing of the Company consummated substantially concurrently with the closing of the Business Combination, which excludes investments by Nature’s Ledger, the Sponsor and their respective affiliates and any financing of Nature’s Ledger, in each case subject to adjustment. If Nature’s Ledger makes this election, it will also receive 250,000 additional Class A ordinary shares (or successor shares) for no additional consideration. The conversion is subject to the approval of the holders of a majority of the Company’s outstanding ordinary shares, and the Sponsor has agreed to vote its ordinary shares in favor of that approval. Shares issued under the NL Note will be entitled to registration rights under the Company’s registration rights agreement, and the Company has agreed to file a registration statement for their resale within 30 days after the closing of the Business Combination and to use its reasonable best efforts to cause it to become effective within 60 days after the closing (or 90 days if the SEC reviews it). The Sponsor has also agreed to waive any adjustment to the conversion ratio of the Class B ordinary shares resulting from the issuance of these shares and not to agree to any lock-up or other transfer restriction on them.

Nasdaq Delisting Determination
 
On October 16, 2026, the Company received a Staff Delisting Determination from Nasdaq, as described in Note 6. On November 11, 2026, the Company requested a hearing before a Nasdaq Hearings Panel, which stays the suspension of the Company’s securities pending the Panel’s decision. The hearing is scheduled for December 1, 2026.

17

Table of Contents
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Globa Terra Acquisition Corporation. References to our “management” or our “management team” refer to our officers and directors and references to the “Sponsor” refer to Globa Terra Management LLC, a Cayman Islands limited liability company. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

Some statements contained in this Quarterly Report are forward-looking in nature. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward- looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements contained in this Quarterly Report may include, but not limited to, statements about:


•
our ability to continue as a going concern;
 

•
our ability to continue to be listed on Nasdaq;
 

•
our ability to select an appropriate target business or businesses;

•
our ability to complete an initial business combination, which is impacted by various factors;

•
our expectations around the performance of a prospective target business or businesses or of markets or industries;


•
the potential liquidity and trading of our public securities;

•
the past performance of our directors, executive officers and their affiliates may not be indicative of future performance of an investment in us;


•
the lack of a market for our securities;

•
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;

•
the trust account not being subject to claims of third parties; and

•
our financial performance following our initial public offering.

The forward-looking statements contained in this Quarterly Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2026, and in Part II, Item 1A of this Quarterly Report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

18

Table of Contents
Overview

We are a blank check company incorporated as a Cayman Islands exempted company on October 18, 2024 for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We intend to effectuate our initial business combination (the “Business Combination”) using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Placement Securities, our shares, debt or a combination of cash, shares and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to raise capital or to complete the Business Combination will be successful.
 
Recent Developments
 
We did not complete our initial business combination by October 9, 2026, the date by which we must complete an initial business combination under our amended and restated memorandum and articles of association if we do not otherwise seek shareholder approval to further extend the time to complete our initial business combination. On November 9, 2026, we held an extraordinary general meeting of shareholders (the “Shareholder Meeting”) to amend our amended and restated memorandum and articles of association (the “Amendments”) to extend the date by which we must consummate an initial business combination from October 9, 2026 to July 9, 2027, consisting of an initial one-month extension from October 9, 2026 to November 9, 2026, followed by up to eight additional one-month extensions on a month-to-month basis, at the sole discretion of our Board of Directors (the “Extension Proposal”). Our shareholders approved the Extension Proposal at the Shareholder Meeting. Following approval of the Extension Proposal, two extension payments were deposited into the Trust Account: (i) on November 10, 2026, $524,987, representing the initial extension payment of $0.03 for each of the 17,499,550 Public Shares in issue as of the date of the Shareholder Meeting, which was deposited prior to the redemption of any Public Shares and extended our deadline from October 9, 2026 to November 9, 2026; and (ii) on November 10, 2026, $40,862, representing the lesser of $0.04 per non-redeemed Public Share and $50,000, which extended our deadline from November 9, 2026 to December 9, 2026, such that the deadline for completing an initial business combination is December 9, 2026, as of the date of this Quarterly Report. On November 10, 2026, the Company filed the Amendments with the Registrar of Companies of the Cayman Islands, effective November 9, 2026. In connection with the Extension Proposal, holders of 16,477,996 Public Shares redeemed their Public Shares for a pro rata portion of the funds in the Trust Account, or approximately $173,652,702 in the aggregate, leaving 1,021,554 Public Shares outstanding. Our Board may, in its sole discretion, further extend the deadline by which we must complete an initial business combination on a month-to-month basis for up to eight (8) additional one-month periods following the initial extension (through July 9, 2027). For each additional extension period, the Sponsor or its affiliates or designees must deposit into the Trust Account the lesser of (x) $0.04 for each Public Share that has not been redeemed, and (y) $50,000, solely for the benefit of the holders of such non-redeemed Public Shares. Pursuant to the Business Combination Agreement described below, our Sponsor and Nature’s Ledger have agreed to fund $250,000 and $750,000, respectively, in connection with the extension of our deadline, evidenced by promissory notes to be repaid at the closing of the Proposed Business Combination, of which $100,000 and $500,000, respectively, had been funded as of November 12, 2026. [The November 2026 extension payments described above were funded with a portion of these amounts.]
 
On October 16, 2026, we received a Staff Delisting Determination from Nasdaq under Listing Rule IM-5101-2(b). On November 11, 2026, we requested a hearing before a Nasdaq Hearings Panel (the “Panel”), which stays the suspension of our securities pending the Panel’s decision. The hearing is scheduled for December 1, 2026. There can be no assurance that the Panel will grant the Company’s request for continued listing. See Notes 1, 6 and 11 to the unaudited condensed financial statements.
 
Proposed Business Combination with Nature’s Ledger
 
On November 8, 2026, we entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”) with Nature’s Ledger Inc., a corporation existing under the Business Corporations Act (Alberta) (the “ABCA”) (“Nature’s Ledger”). Pursuant to the Business Combination Agreement, 1587815 B.C. Ltd., a company existing under the laws of British Columbia and an unlisted reporting issuer in the Provinces of British Columbia and Alberta (“BCCo” and, together with Nature’s Ledger, the “Company Parties”), is expected to become a party to the Business Combination Agreement by entering into a joinder. The Business Combination Agreement is effective and binding on us and Nature’s Ledger irrespective of whether BCCo executes a joinder. Nature’s Ledger is engaged in the origination, development, verification, aggregation, registration, marketing and sale of carbon credits and environmental attributes, together with related advisory, project finance, measurement, reporting and verification, and registry and tokenization activities. Our Board of Directors, including a majority of our independent directors, has approved the Business Combination Agreement and the transactions contemplated thereby and resolved to recommend that our shareholders approve the proposals to be presented to them in connection therewith.

The Business Combination. Pursuant to the Business Combination Agreement, and subject to the terms and conditions set forth therein, among other things: (i) BCCo will continue from British Columbia to Alberta under the ABCA; (ii) Nature’s Ledger will complete the PIPE Financing described below; (iii) we will merge with and into an exempted company to be incorporated under the Companies Act (As Revised) of the Cayman Islands as our wholly-owned subsidiary (“Pubco”), which will join the Business Combination Agreement by joinder, with Pubco as the surviving company (the “SPAC Merger”); (iv) Pubco will continue from the Cayman Islands to Alberta under the ABCA and change its name to “Nature’s Ledger” or such other name as Nature’s Ledger designates (the “Continuance”); and (v) pursuant to a plan of arrangement under Section 193 of the ABCA (the “Arrangement”), no earlier than the day after the Continuance, Nature’s Ledger, BCCo and a corporation to be incorporated under the ABCA as our wholly-owned subsidiary (“AmalSub”) will amalgamate (the “Amalgamation”) to form a corporation (“Amalco”) that will continue as a wholly-owned subsidiary of Pubco (the SPAC Merger, the Continuance, the Amalgamation and the other transactions contemplated by the Business Combination Agreement, collectively, the “Proposed Business Combination”). The Arrangement is subject to the approval of the Court of King’s Bench of Alberta. As a result of the Proposed Business Combination, Pubco will be the publicly traded parent company and Amalco will be its wholly-owned subsidiary.

Treatment of Globa Terra Securities. Our public shareholders will be entitled to redeem their Class A ordinary shares in accordance with an amendment to our existing amended and restated memorandum and articles of association (the “Articles Amendment”), providing for the redemption of such shares following shareholder approval, but prior to the SPAC Merger. Immediately prior to the SPAC Merger, each of our Class B ordinary shares will convert into one Class A ordinary share and each of our units will separate into its component securities. At the SPAC Merger, (i) each Class A ordinary share then outstanding (other than shares that are redeemed, cancelled or held by dissenting shareholders) will convert into one common share of Pubco (“Pubco Common Share”); (ii) each of our warrants will become a warrant to acquire Pubco Common Shares on the terms of our existing warrant agreement; and (iii) each of our rights will become a right to receive one-tenth of one Pubco Common Share on the terms of our existing rights agreement.

Arrangement Consideration. Pursuant to the Arrangement, (i) each Nature’s Ledger Class A share (other than dissenting shares, shares held by Pubco or AmalSub, and shares issued upon conversion of the PIPE securities) will be exchanged for Pubco Common Shares based on an exchange ratio (the “NL Exchange Ratio”); (ii) each Nature’s Ledger Class G preferred share will be exchanged for a number of Pubco Common Shares equal to the NL Exchange Ratio multiplied by the number of Nature’s Ledger Class A shares into which it is then convertible; (iii) each BCCo share will be exchanged for Pubco Common Shares based on a separate exchange ratio; and (iv) each Nature’s Ledger warrant will be exchanged for a replacement warrant, with the number of shares and exercise price adjusted by the NL Exchange Ratio. The exchange ratios are based on a pre-money equity value of Nature’s Ledger of $323,775,000 (increased by the value, at $10.00 per share, of the Sponsor PIPE Facilitation Shares described below if the PIPE Financing closes, and decreased by the value of any Pubco Common Shares issued in respect of BCCo shares in excess of 82,500), a pre-money equity value of BCCo of $825,000 (with no more than 165,000 Pubco Common Shares issuable in respect of all BCCo shares), and a value of $10.00 per Pubco Common Share. The parties intend that the Pubco Common Shares and replacement warrants issued pursuant to the Arrangement (other than in respect of the PIPE Financing) will be issued in reliance on the exemption from registration provided by Section 3(a)(10) of the Securities Act.

19

Table of Contents
Earnout. Holders of Nature’s Ledger Class A shares (including shares issued upon conversion of the PIPE securities) and Class G preferred shares immediately prior to the Amalgamation will be entitled to receive, on a pro rata basis, up to 6,557,772 additional Pubco Common Shares during the five years following the closing, as follows: (i) 50% upon the earlier of the volume-weighted average price of the Pubco Common Shares equaling or exceeding $12.50 for any 20 trading days within a 30-consecutive-trading-day period, or Pubco achieving EBITDA of at least $11.1 million for 2027; and (ii) the remaining 50% (or 100%, if the first tranche has not been issued) upon the earlier of such volume-weighted average price equaling or exceeding $15.00, or Pubco achieving EBITDA of at least $32.8 million for 2028. The earnout shares are subject to acceleration or termination upon a change of control of Pubco.

PIPE Financing. Nature’s Ledger has agreed to use its reasonable best efforts to sell subscription receipts at a price of $10.00 per security, on a best-efforts basis, for targeted gross proceeds of $10,000,000 (the “PIPE Financing”), with each investor to receive one Pubco Common Share for each $10.00 subscribed. To facilitate the PIPE Financing, (i) the Sponsor will forfeit up to 500,000 Founder Shares (the “Sponsor PIPE Facilitation Shares”), and (ii) the Pubco Common Shares allocable to the PIPE investors will be increased by up to 3,000,000 shares plus a number of shares equal to the Sponsor PIPE Facilitation Shares, in each case as mutually determined by the Sponsor and Nature’s Ledger, as further described in the Business Combination Agreement.

Governance. Immediately after the closing, the board of directors of Pubco will consist of five directors, two of whom will be designated by Nature’s Ledger, two of whom will be designated by the Sponsor and one of whom will be jointly designated, a majority of whom must be independent under Nasdaq rules. The chief executive officer designated by Nature’s Ledger will serve as chairperson with a casting vote.

Covenants. The Business Combination Agreement contains customary representations, warranties and covenants of the parties, including covenants relating to the conduct of business prior to the closing and mutual exclusivity. Among other things, (i) Pubco (or Globa Terra) will file a registration statement on Form F-4 or Form S-4 with the SEC, with the Company Parties or Amalco as co-registrants where required (the “Registration Statement”); (ii) we will hold an extraordinary general meeting of our shareholders to approve the Proposed Business Combination and related proposals, and the Company Parties will obtain the approval of their shareholders and the interim and final orders of the court; (iii) the Company Parties will deliver PCAOB-audited financial statements by December 31, 2026 and their disclosure letters by December 15, 2026; (iv) the Sponsor and Nature’s Ledger have agreed to fund $250,000 and $750,000, respectively, in connection with the extension of our deadline to complete a business combination, evidenced by promissory notes issued by us, of which $100,000 and $500,000, respectively, had been funded as of November 12, 2026; (v) Pubco will adopt an omnibus equity incentive plan with an initial reserve equal to 15% of the Pubco Common Shares outstanding after the closing, subject to the approval of our shareholders; and (vi) Pubco will enter into an advisor agreement with affiliates of the Sponsor for advisory services in exchange for equity, subject to the approval of a majority of our disinterested directors and Pubco’s independent directors.

Conditions to Closing. The closing of the Proposed Business Combination is subject to customary conditions, including, among others: (i) approval of the Arrangement by the shareholders of Nature’s Ledger and BCCo; (ii) approval by our shareholders of the proposals to be presented at our extraordinary general meeting, including the Articles Amendment; (iii) receipt of the interim and final orders of the court; (iv) the Registration Statement having become effective; (v) the Continuance and the continuance of BCCo having become effective; (vi) approval of the listing of the Pubco Common Shares on Nasdaq; (vii) receipt of required regulatory approvals and the absence of any law or order prohibiting the Proposed Business Combination; (viii) the accuracy of the parties’ representations and warranties and performance of their covenants, subject to applicable materiality standards; (ix) the absence of a material adverse effect on the Company Parties; (x) dissent rights not having been exercised with respect to more than 5% of the outstanding shares of Nature’s Ledger or BCCo; (xi) delivery of the PCAOB-audited financial statements; (xii) execution of the lock-up agreements and specified executive employment agreements; and (xiii) receipt by our Board of Directors of a fairness opinion.

Termination. The Business Combination Agreement may be terminated under certain customary and limited circumstances prior to the closing, including: (i) by mutual written agreement; (ii) by us, Nature’s Ledger or BCCo if the closing has not occurred by July 9, 2027 (which date may be extended, but not beyond the end of our combination period), if the Proposed Business Combination is permanently enjoined, or if the required shareholder approvals are not obtained; (iii) by us for an uncured breach by a Company Party, upon a material adverse effect on the Company Parties, or if the PCAOB-audited financial statements are not delivered by January 31, 2027; (iv) by Nature’s Ledger or BCCo for an uncured breach by us or AmalSub, a change in our Board of Directors’ recommendation, or a material breach of our exclusivity obligations; and (v) by us, on the recommendation of a majority of our independent directors, within 15 business days after receipt of the Company Parties’ disclosure letters if they disclose a material matter, or if the disclosure letters are not timely delivered and such failure is not cured within ten business days. In certain circumstances, a terminating party is entitled to reimbursement of its documented out-of-pocket transaction expenses, which, in our case, are payable only from funds held outside the Trust Account.

Related Agreements. Concurrently with the execution of the Business Combination Agreement, (i) we, the Sponsor, Nature’s Ledger and certain of our other shareholders entered into a sponsor support agreement (the “Sponsor Support Agreement”), pursuant to which, among other things, the Sponsor and such shareholders agreed to vote in favor of the Proposed Business Combination and any extension of our deadline to complete a business combination, to comply with the letter agreement entered into in connection with our Initial Public Offering (including its waiver of redemption rights), to convert their Class B ordinary shares into Class A ordinary shares immediately prior to the SPAC Merger, to waive anti-dilution rights, and not to transfer their securities, subject to certain exceptions; and (ii) we, Nature’s Ledger and certain shareholders of Nature’s Ledger entered into a company support agreement (the “Company Support Agreement”), pursuant to which, among other things, such shareholders agreed to vote in favor of the Business Combination Agreement and the Arrangement, to waive dissent rights, and not to transfer their Nature’s Ledger shares, subject to certain exceptions. In addition, at or prior to the closing, the Sponsor, our directors and officers, the founders, directors, officers and 5% holders of Nature’s Ledger, and certain insiders of BCCo will enter into lock-up agreements for a period of 12 months following the closing (subject to any shorter period applicable to the Sponsor and our directors and officers under their existing letter agreement), and Pubco, the Sponsor and certain securityholders of the Company Parties will enter into an amended and restated registration rights agreement, pursuant to which Pubco will be required to file a resale registration statement within 30 days after the closing, together with customary demand and piggyback rights.

The foregoing descriptions of the Business Combination Agreement, the Sponsor Support Agreement and the Company Support Agreement do not purport to be complete and are qualified in their entirety by the full text of such agreements, copies of which are filed as Exhibits 2.1, 10.1 and 10.2, respectively, to our Current Report on Form 8-K filed with the SEC on November 12, 2026.

20

Table of Contents
Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from October 18, 2024 (inception) through September 30, 2026 have been organizational activities, those necessary to prepare for the Initial Public Offering, described below, and identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. Subsequent to the Initial Public Offering, we generate non-operating income in the form of interest income on the cash held in the trust account (the “Trust Account”). We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three and nine months ended September 30, 2026, we had net income of $1,476,230 and $4,170,691, respectively, which consisted of interest income earned on the cash held in the Trust Account of $1,613,349 and $4,721,006, respectively, partially offset by formation and operating expenses of $137,119 and $550,315, respectively.
 
For the three and nine months ended September 30, 2025, we had net income of $1,312,252, which consisted of interest income earned on the cash held in the Trust Account of $1,668,159, partially offset by formation and operating expenses of $355,907.
 
Liquidity and Capital Resources

Until the consummation of the Initial Public Offering, our liquidity needs were satisfied through receipt of $25,000 from the sale of Class B ordinary shares, par value $0.0001 per share (the “founder shares”), to the Sponsor and up to $450,000 in loans from the Sponsor under an unsecured promissory note, as amended from time to time, the balance of which was partial consideration for the Sponsor’s purchase of Private Placement Securities, and therefore deemed repaid upon the closing of the Initial Public Offering.

On July 10, 2025, we consummated the initial public offering (the “Initial Public Offering”) of 17,499,550 units (the “Units”), including 2,282,550 Units issued pursuant to the exercise of the underwriters’ over-allotment option in full. Each Unit consists of one Class A ordinary share, $0.0001 par value per share (the “Class A Ordinary Shares”), three-fourths of one redeemable warrant (the “Public Warrants”), with each whole Public Warrant entitling the holder thereof to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, subject to adjustment, and one right to receive one-tenth of a Class A Ordinary Share upon our consummation of the Business Combination. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $174,995,500 (before underwriting discounts and commissions and offering expenses).

Simultaneously with the closing of the Initial Public Offering, we completed the private placements of an aggregate of (a) 394,267 private placement units (the “Private Placement Units”) and (b) 788,534 restricted Class A ordinary shares (the “Restricted Class A Shares” and, together with the Private Placement Units, the “Private Placement Securities”) at a combined price of $10.00 per Private Placement Security for an aggregate purchase price of $3,154,136 (the “Private Placements”). The Private Placement Units, which were purchased by the Sponsor and an institutional investor, are identical to the Units, except that, they (i), subject to certain limited exceptions, will be subject to transfer restrictions until 180 days following the consummation of the Business Combination and (ii) will be entitled to registration rights. In addition, the warrants included in the Private Placement Units (the “Private Placement Warrants”) are not redeemable by the Company. The Restricted Class A Shares are Class A Ordinary Shares that have had their voting, redemption and transfer rights contractually waived until such time as we complete the Business Combination.

21

Table of Contents
Following the closing of the Initial Public Offering and the Private Placements, a total of $174,995,500 was placed in the Trust Account. We incurred $3,195,665 of transaction costs, consisting of $750,000 of cash underwriting fee,  $462,925 of financial advisor expenses and consulting fees and $1,982,740 of other offering costs and expenses.

For the nine months ended September 30, 2026, cash used in operating activities was $435,535. Net income of $4,170,691 was affected by interest earned on cash held in the Trust Account of $4,721,006, a decrease in cash of $17,756 due to a change in prepaid expenses and an increase in cash of $132,536 due to a change in accrued expenses.

For the nine months ended September 30, 2026 and September 30, 2025, cash used in investing activities was $0 and $174,995,500, respectively.

Net cash used in financing activities was $10,690 for the nine months ended September 30, 2026, and net cash provided by financing activities was $175,943,085 for the nine months ended September 30, 2025.

As of September 30, 2026, we had cash held in the Trust Account of $183,101,959. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, to complete our initial business combination. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of September 30, 2026, we had cash of $104,902 in our operating bank account. We intend to use the funds held outside the trust account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete our initial business combination.

In order to fund working capital deficiencies or finance transaction costs in connection with the Business Combination, the Sponsor, an affiliate of the Sponsor or certain officers and directors of the Company may, but are not obligated to, loan us funds as may be required (the “Working Capital Loans”). If we complete the Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that the Business Combination is not consummated, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $2,500,000 of such Working Capital Loans may be convertible into private units at a price of $10.00 per unit at the option of the lender. In addition, our board of directors may approve additional Working Capital Loans from the Sponsor or third parties for the purpose of funding working capital, which loans may be converted into our private units, shares, rights or warrants. The private units would be identical to the Private Placement Units.

As of September 30, 2026, we had cash of $104,902 held outside the Trust Account and working capital of $185,598. We may need to raise additional funds, including through loans from our Sponsor, to fund our operations, the costs of the Extension Proposal and our Nasdaq appeal, and any extension contributions. Subsequent to September 30, 2026, the Sponsor and Nature’s Ledger funded $100,000 and $500,000, respectively, of their $250,000 and $750,000 extension funding commitments under the Business Combination Agreement, evidenced by promissory notes issued by us. The Sponsor’s note is non-interest-bearing and is repayable upon the closing of the Business Combination. The note issued to Nature’s Ledger, dated as of October 9, 2026, has a principal amount of up to $750,000, bears simple interest at 8.00% per annum (or 12.00% per annum on amounts converted into shares), and is payable on the earlier of the consummation of our initial business combination and the date our winding up becomes effective. Before the closing, Nature’s Ledger may elect to convert the outstanding principal and accrued interest into our Class A ordinary shares (or shares of our successor) at the lower of $5.00 per share and the lowest effective price paid in a qualifying concurrent financing, and would also receive 250,000 additional shares, subject to shareholder approval; any such issuance would dilute our public shareholders. If we do not complete a business combination, the note will become payable when our winding up becomes effective, and because Nature’s Ledger has waived any claim against the Trust Account, it could be repaid only from funds held outside the Trust Account. See Notes 5 and 11 to the unaudited condensed financial statements. [A portion of these funds was used to make the extension payments of $524,987 and $40,862 deposited into the Trust Account in November 2026, which extended our deadline to complete a business combination to December 9, 2026.] In addition, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating the Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to the Business Combination. Moreover, we may need to obtain additional financing either to complete the Business Combination or because we become obligated to redeem a significant number of our public shares upon completion of the Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. If we raise additional funds through equity or convertible debt issuances, our public shareholders may suffer significant dilution, and these securities could have rights that rank senior to our public shares. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to our equity securities and could contain covenants that restrict our operations. Further, due to the anti-dilution rights of our founder shares, our public shareholders may incur material dilution. In addition, we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of the Initial Public Offering and Private Placements, and, as a result, if the cash portion of the purchase price exceeds the amount available from the Trust Account, net of amounts needed to satisfy redemptions by public shareholders, we may be required to seek additional financing to complete such proposed Business Combination. We may also obtain financing prior to the closing of the Business Combination to fund our working capital needs and transaction costs in connection with our search for and completion of the Business Combination. There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with the Business Combination, any backstop or similar agreements or otherwise. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of the Business Combination. If we are unable to complete the Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.
 
Going Concern
 
As described in Note 1 to the unaudited condensed financial statements, we did not complete a business combination by October 9, 2026, and we have received a Staff Delisting Determination from Nasdaq. Although our shareholders approved the Extension Proposal on November 9, 2026, our ability to extend beyond each monthly deadline depends on the funding of the related contributions by our Sponsor, Nature’s Ledger or their designees, and there can be no assurance that we will complete our proposed business combination with Nature’s Ledger or any other business combination by July 9, 2027. These conditions, together with our limited cash outside the trust account, raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed financial statements included in this Quarterly Report are issued.

22

Table of Contents
Off-Balance Sheet Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2026. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations or operating lease obligations. As of September 30, 2026, we had $1,255,359 of fees owed to certain service providers whose payment has been deferred until the completion of our initial business combination, which are presented as long-term liabilities.

We have agreed to pay our Sponsor $15,000 per month for office space, administrative and shared personnel support services.

We granted the underwriter a 45-day option from the date of the Initial Public Offering to purchase up to 2,282,550 additional Units at the Initial Public Offering price to cover over-allotments, if any. The underwriters fully exercised the over-allotment option as of July 9, 2025.

The underwriters were entitled to a cash underwriting discount of $750,000, which was paid upon the closing of the Initial Public Offering.

Critical Accounting Estimates

The preparation of the unaudited condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could materially differ from those estimates. As of September 30, 2026, we did not have any critical accounting estimates.

Item 3.
Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information otherwise required under this item.

Item 4.
Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (together, the “Certifying Officers”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

23

Table of Contents
Under the supervision and with the participation of our management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were effective as of the end of the quarterly period ended September 30, 2026.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.
Legal Proceedings

None.

Item 1A.
Risk Factors

Investing in our securities involves a high degree of risk. In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026 and June 30, 2026, filed with the SEC on May 14, 2026 and August 14, 2026, respectively, and our definitive proxy statement filed with the SEC on October 26, 2026, and the additional risk factors set forth below, which could materially affect our business, financial condition, or future results.
 
Nasdaq has determined to delist our securities, and the Nasdaq Hearings Panel may not grant our request for continued listing.
 
On October 16, 2026, Nasdaq notified us that, because we did not complete our initial business combination within the time period specified in the registration statement for our initial public offering, we did not comply with Nasdaq IM-5101-2(b) and that Nasdaq had initiated procedures to delist our securities. We requested a hearing before the Panel, which stays the suspension of our securities pending the Panel’s decision. The hearing is scheduled for December 1, 2026. The Panel may deny our request for continued listing. In addition, redemptions of our public shares in connection with the Extension Proposal have substantially reduced the number of our Public Shares outstanding, which may cause us to fall out of compliance with other Nasdaq continued listing requirements. If our securities are delisted and we are not able to list them on another national securities exchange, they may be quoted, if at all, on an over-the-counter market, which could result in limited availability of market quotations, reduced liquidity, a determination that our Class A ordinary shares are a “penny stock,” reduced news and analyst coverage, a decreased ability to obtain additional financing, the loss of “covered securities” status under the National Securities Markets Improvement Act of 1996, and may make it more difficult for us to complete our proposed business combination with Nature’s Ledger or any other business combination.
 
There is no assurance that the extension will enable us to complete a business combination.
 
On November 9, 2026, our shareholders approved the Extension Proposal, which permits us to extend the date by which we must consummate a business combination from October 9, 2026 to July 9, 2027, consisting of an initial one-month extension to November 9, 2026, followed by up to eight additional one-month extensions at the sole discretion of our Board of Directors. Each additional monthly extension is available only if our Sponsor or its affiliates or designees deposit into the trust account the lesser of $0.04 per public share that has not been redeemed and $50,000. In November 2026, extension payments of $524,987 and $40,862 were deposited into the trust account, extending our deadline to December 9, 2026. Under the Business Combination Agreement, our Sponsor and Nature’s Ledger have agreed to fund $250,000 and $750,000, respectively, in connection with the extension of our deadline, of which $100,000 and $500,000, respectively, had been funded as of November 12, 2026. Neither our Sponsor nor Nature’s Ledger is otherwise obligated to fund the monthly extension contributions, and if the Business Combination Agreement is terminated or either party fails to fund its commitment, the remaining contributions may not be made. If a contribution is not made when due, we would not be able to extend for the applicable period and would be required to cease operations, redeem 100% of our outstanding public shares and liquidate, even if we have entered into a definitive business combination agreement, in which case our warrants and rights would expire worthless. Even with the full extension, we may not be able to complete a business combination by July 9, 2027.
 
Redemptions in connection with the extension have significantly reduced the funds in our trust account, and further redemptions in connection with our proposed business combination may leave us with insufficient cash to complete it.
 
In connection with the Extension Proposal, holders of 16,477,996 public shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account, substantially reducing the amount held in the Trust Account. We will be required to offer our public shareholders redemption rights again in connection with any shareholder vote to approve our proposed business combination with Nature’s Ledger. Even if the business combination is approved by our shareholders, redemptions may leave us with insufficient cash to satisfy any minimum cash condition or to consummate the business combination on commercially acceptable terms, or at all, and the reduced public float may adversely affect the liquidity and trading price of our securities.
 
Our proposed business combination with Nature’s Ledger may not be completed in a timely manner or at all.
 
On November 8, 2026, we entered into the Business Combination Agreement. Consummation of the business combination is subject to a number of conditions, including but not limited to approval by our shareholders and by the shareholders of Nature’s Ledger and BCCo, approval of the plan of arrangement by the Court of King’s Bench of Alberta, the effectiveness of the Registration Statement, approval of the listing of the combined company’s common shares on Nasdaq, receipt of required regulatory approvals, delivery by the Company Parties of PCAOB-audited financial statements, dissent rights not having been exercised with respect to more than 5% of the shares of Nature’s Ledger or BCCo, and receipt by our Board of Directors of a fairness opinion. In addition, the business combination agreement may be terminated by either party if the closing has not occurred by July 9, 2027, and by us if the Company Parties do not deliver PCAOB-audited financial statements by January 31, 2027. Nature’s Ledger’s targeted $10,000,000 PIPE financing is being conducted on a best-efforts basis and may not be completed. Many of these conditions are outside our control. If the conditions are not satisfied or waived, the business combination agreement is terminated, or the business combination is not completed before our deadline, as it may be extended, the business combination will not be completed, which may adversely affect the price of our securities, and we may be forced to liquidate. We have incurred and will continue to incur significant transaction costs in connection with the proposed business combination, and we may become subject to legal proceedings relating to it.
 
24

Table of Contents
The Extension Amendment was approved and became effective after the expiration of our original Combination Period, and its validity may be challenged.

Our Amended and Restated Memorandum and Articles of Association and the Investment Management Trust Agreement required us, if we did not complete a business combination by October 9, 2026, to cease operations, redeem 100% of our public shares within ten business days and liquidate the Trust Account. We did not complete a business combination or deposit funds to effect either three-month paid extension by that date, and we did not redeem our public shares or liquidate the Trust Account. Our shareholders did not approve the Extension Amendment until the Shareholder Meeting on November 9, 2026, and we filed the Extension Amendment with the Registrar of Companies of the Cayman Islands on November 10, 2026, effective November 9, 2026, with the initial one-month extension applying retroactively from October 9, 2026. Because the Extension Amendment was adopted after our original deadline had passed, public shareholders, the trustee or others may assert that our obligation to redeem the public shares had already arisen and could not be avoided by a subsequent amendment, that the Extension Amendment is invalid or unenforceable, or that we, our Sponsor or our directors and officers breached our Amended and Restated Memorandum and Articles of Association, the Investment Management Trust Agreement or fiduciary or other duties. Although, as of November 16, 2026, we are not aware of any such claims, they could be brought under Cayman Islands law or other applicable law, and there is limited precedent addressing these questions. If a court or other tribunal were to determine that the Extension Amendment is invalid or ineffective, we may be required to redeem all of our public shares and liquidate, in which case our warrants and rights would expire worthless and we would be unable to complete our proposed business combination with Nature’s Ledger. Any such claim, even if without merit, could be costly to defend, divert the attention of our management, delay or prevent the completion of our proposed business combination, give rise to indemnification obligations, adversely affect the outcome of the Panel proceeding, and adversely affect the price of our securities.

Our Sponsor and our officers and directors have interests in the Extension and our proposed business combination with Nature’s Ledger that are different from, or in addition to, those of our public shareholders, which may result in conflicts of interest.

When considering our Board of Directors’ recommendation that shareholders approve the Extension Proposal and, in the future, our proposed business combination with Nature’s Ledger, our public shareholders should be aware that our Sponsor and our officers and directors have interests that may differ from, or be in addition to, those of our public shareholders. These interests include, among others: (i) our Sponsor paid an aggregate of $25,000, or approximately $0.0043 per share, for 5,833,183 Founder Shares, certain of which it has transferred to our independent directors, members of our management team and an advisor, and these shares would have a significantly higher value upon completion of a business combination even if the trading price of the combined company’s shares declines substantially below $10.00 per share, but would be worthless if we liquidate; (ii) our Sponsor purchased Private Placement Units and Restricted Class A Shares for $2,854,136, and the Founder Shares, the Restricted Class A Shares and the warrants and rights included in the Private Placement Units will not be entitled to liquidating distributions from the Trust Account and will be worthless if we do not complete a business combination; (iii) our Sponsor has agreed to fund up to $250,000 in connection with the extension of our deadline under a non-interest-bearing promissory note that is repayable only upon the closing of the proposed business combination, and certain service providers have agreed to defer fees of $1,255,359 as of September 30, 2026 until the completion of a business combination; (iv) our Sponsor is a party to the promissory note we issued to Nature’s Ledger, under which Nature’s Ledger may convert the outstanding principal and accrued interest into our Class A ordinary shares at the lower of $5.00 per share and the lowest effective price paid in a qualifying concurrent financing and receive 250,000 additional shares, and our Sponsor has agreed to vote its ordinary shares in favor of that issuance and to waive any resulting adjustment to the conversion ratio of the Class B ordinary shares; (v) under the Sponsor Support Agreement, our Sponsor and certain of our other shareholders have agreed to vote in favor of the proposed business combination and any extension of our deadline; (vi) following the closing, our Sponsor will have the right to designate two of the five members of the board of directors of Pubco and to jointly designate a third, and Pubco is expected to enter into an advisor agreement with affiliates of our Sponsor for advisory services in exchange for equity; (vii) our Sponsor will forfeit up to 500,000 Founder Shares in connection with the PIPE Financing and, together with Nature’s Ledger, will determine any additional Pubco Common Shares to be issued to PIPE investors; (viii) we pay our Sponsor or an affiliate $15,000 per month for office space, administrative and shared personnel support services; and (ix) our officers and directors may have fiduciary or contractual obligations to other entities and are not required to devote their full time to our affairs. As a result of these interests, our Sponsor and our officers and directors have an incentive to complete a business combination, including the proposed business combination with Nature’s Ledger, rather than liquidate, even if the business combination is with a less favorable target or on terms less favorable to our public shareholders, and these interests may have influenced their decision to approve the Extension Amendment and the Business Combination Agreement and to recommend that shareholders vote in favor of these proposals.

25

Table of Contents
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.

On October 18, 2024, the Sponsor received 7,187,500 founder shares in exchange for a payment of $25,000. On March 25, 2025, the Sponsor surrendered 1,354,317 founder shares for no consideration and thereafter held 5,833,183 founder shares. Accordingly, the Sponsor’s initial investment in us of $25,000 resulted in an effective purchase price of $0.0043 per share for the 5,833,183 founder shares (up to 760,850 of which were subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option was exercised). The underwriters fully exercised the over-allotment option as of July 9, 2025. The foregoing issuance of securities was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

On July 10, 2025, we consummated the Initial Public Offering of 17,499,550 Units, including 2,282,550 Units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $174,995,500. Simultaneously with the closing of the Initial Public Offering, we consummated the Private Placements of an aggregate of (a) 394,267 Private Placement Units and (b) 788,534 Restricted Class A Shares, at a combined price of $10.00 per Private Placement Security for an aggregate purchase price of $3,154,136. The Private Placement Units, which were purchased by the Sponsor and an institutional investor, are identical to the Units, except that, they (i), subject to certain limited exceptions, will be subject to transfer restrictions until 180 days following the consummation of the Business Combination and (ii) will be entitled to registration rights. In addition, the Private Placement Warrants are not redeemable by the Company. The Restricted Class A Shares are Class A Ordinary Shares that have had their voting, redemption and transfer rights contractually waived until such time as we complete the Business Combination. The Private Placements were made in reliance on an exemption to “Accredited Investors” within the meaning of Section 501(a) of Regulation D under the Securities Act and similar exemptions under state law or a non-U.S. Person under Regulation S under the Securities Act.

Of the gross proceeds received from the Initial Public Offering and the Private Placements, an aggregate of $174,995,500 was placed in the Trust Account. The proceeds held in the Trust Account will be held or invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of the Business Combination and (ii) the distribution of the funds in the Trust Account to our shareholders. As of September 30, 2026, the funds in the Trust Account were held as cash on deposit with a financial institution.

We incurred $3,195,665 of transaction costs, consisting of $750,000 of cash underwriting fee, approximately $462,925 of financial advisor expenses and consulting fees and $1,982,740 of other offering costs and expenses.

For a description of the use of the proceeds generated in the Initial Public Offering, see Part I, Item 2 of this Quarterly Report on Form 10-Q.

Item 3.
Defaults Upon Senior Securities

None.

26

Table of Contents
Item 4.
Mine Safety Disclosures

Not applicable.

Item 5.
Other Information

None.

Item 6.
Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.
 
Description of Exhibit
2.1†
 
Business Combination Agreement, dated as of November 8, 2026, by and between Globa Terra Acquisition Corporation and Nature’s Ledger Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No. 001-42736), filed with the SEC on November 12, 2026).
3.1
 
Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-42736), filed with the SEC on July 10, 2025).
3.2
 
Amendments to the Amended and Restated Memorandum and Articles of Association of Globa Terra Acquisition Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-42736), filed with the SEC on November 10, 2026).
10.1
 
Sponsor Support Agreement, dated as of November 8, 2026, by and among Globa Terra Acquisition Corporation, Globa Terra Management LLC, Nature’s Ledger Inc. and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-42736), filed with the SEC on November 12, 2026).
10.2
 
Company Support Agreement, dated as of November 8, 2026, by and among Globa Terra Acquisition Corporation, Nature’s Ledger Inc. and the shareholders of Nature’s Ledger Inc. party thereto (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-42736), filed with the SEC on November 12, 2026).
31.1*
 
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
 
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**
 
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**
 
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
Inline XBRL Instance Document.
101.SCH
 
Inline XBRL Taxonomy Extension Schema Document.
101.CAL
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
 
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
 
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
 
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*
Filed herewith.
†
Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
**
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

27

Table of Contents
SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
GLOBA TERRA ACQUISITION CORPORATION
     
Date: November 17, 2026
By:
/s/ Agustin Tristan Aldave
 
Name:
Agustin Tristan Aldave
 
Title:
Chief Executive Officer
   
(Principal Executive Officer)
     
Date: November 17, 2026
By:
/s/ Katherine Chiles
 
Name:
Katherine Chiles
 
Title:
Chief Financial Officer
   
(Principal Financial and Accounting Officer)


28

00-0000000 1.25 2.50 0.75 0.1 0.75 0.1 1 0.1 0.1 0.1 0002043766 false Q3 --12-31 0002043766 2026-01-01 2026-09-30 0002043766 gteru:UnitsMember 2026-01-01 2026-09-30 0002043766 us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0002043766 gteru:PublicWarrantMember 2026-01-01 2026-09-30 0002043766 gteru:PublicRightsMember 2026-01-01 2026-09-30 0002043766 us-gaap:CommonClassAMember 2026-11-17 0002043766 us-gaap:CommonClassBMember 2026-11-17 0002043766 2026-09-30 0002043766 2025-12-31 0002043766 us-gaap:CommonClassAMember 2026-09-30 0002043766 us-gaap:CommonClassAMember 2025-12-31 0002043766 us-gaap:CommonClassBMember 2026-09-30 0002043766 us-gaap:CommonClassBMember 2025-12-31 0002043766 2026-07-01 2026-09-30 0002043766 2025-07-01 2025-09-30 0002043766 2025-01-01 2025-09-30 0002043766 gteru:RedeemableSharesMember 2026-07-01 2026-09-30 0002043766 gteru:RedeemableSharesMember 2025-07-01 2025-09-30 0002043766 gteru:RedeemableSharesMember 2026-01-01 2026-09-30 0002043766 gteru:RedeemableSharesMember 2025-01-01 2025-09-30 0002043766 gteru:NonRedeemableSharesMember 2026-07-01 2026-09-30 0002043766 gteru:NonRedeemableSharesMember 2025-07-01 2025-09-30 0002043766 gteru:NonRedeemableSharesMember 2026-01-01 2026-09-30 0002043766 gteru:NonRedeemableSharesMember 2025-01-01 2025-09-30 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-12-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-12-31 0002043766 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002043766 us-gaap:RetainedEarningsMember 2025-12-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0002043766 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0002043766 2026-01-01 2026-03-31 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-03-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-03-31 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0002043766 us-gaap:RetainedEarningsMember 2026-03-31 0002043766 2026-03-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0002043766 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0002043766 2026-04-01 2026-06-30 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-06-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-06-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002043766 us-gaap:RetainedEarningsMember 2026-06-30 0002043766 2026-06-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002043766 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-09-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-09-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002043766 us-gaap:RetainedEarningsMember 2026-09-30 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0002043766 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002043766 us-gaap:RetainedEarningsMember 2024-12-31 0002043766 2024-12-31 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-03-31 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-03-31 0002043766 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002043766 us-gaap:RetainedEarningsMember 2025-03-31 0002043766 2025-03-31 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-06-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-06-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002043766 us-gaap:RetainedEarningsMember 2025-06-30 0002043766 2025-06-30 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002043766 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0002043766 srt:MaximumMember us-gaap:CommonClassBMember 2025-03-31 0002043766 us-gaap:CommonClassBMember 2025-03-25 0002043766 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-09-30 0002043766 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-09-30 0002043766 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002043766 us-gaap:RetainedEarningsMember 2025-09-30 0002043766 2025-09-30 0002043766 srt:MinimumMember 2024-10-18 2024-10-18 0002043766 us-gaap:SubsequentEventMember 2026-11-01 2026-11-30 0002043766 us-gaap:SubsequentEventMember 2026-11-09 2026-11-09 0002043766 us-gaap:SubsequentEventMember 2026-11-09 0002043766 us-gaap:IPOMember 2025-07-10 0002043766 us-gaap:OverAllotmentOptionMember 2025-07-10 0002043766 us-gaap:IPOMember 2025-07-10 2025-07-10 0002043766 us-gaap:PrivatePlacementMember 2025-07-10 2025-07-10 0002043766 us-gaap:RestrictedStockMember us-gaap:CommonClassAMember 2025-07-10 2025-07-10 0002043766 us-gaap:PrivatePlacementMember 2025-07-10 0002043766 gteru:RestrictedClassASharesMember 2025-07-10 2025-07-10 0002043766 2025-07-10 2025-07-10 0002043766 2025-07-10 0002043766 srt:MinimumMember 2026-01-01 2026-09-30 0002043766 srt:MinimumMember 2026-09-30 0002043766 gteru:PublicSharesMember 2026-09-30 0002043766 gteru:PublicSharesMember 2026-01-01 2026-09-30 0002043766 srt:MaximumMember 2026-09-30 0002043766 us-gaap:IPOMember 2026-09-30 0002043766 srt:MaximumMember gteru:PublicSharesMember us-gaap:IPOMember 2026-09-30 0002043766 us-gaap:CashMember 2026-09-30 0002043766 us-gaap:CashMember 2025-12-31 0002043766 gteru:TrustAccountMember 2026-09-30 0002043766 gteru:TrustAccountMember 2025-12-31 0002043766 gteru:SponsorAndPrivatePlacementInvestorMember us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0002043766 2025-01-01 2025-03-31 0002043766 2025-01-01 2025-12-31 0002043766 us-gaap:OverAllotmentOptionMember 2025-07-10 2025-07-10 0002043766 us-gaap:CommonClassAMember 2025-07-10 0002043766 gteru:RedeemableWarrantsMember 2025-07-10 0002043766 us-gaap:RightsMember 2025-07-10 0002043766 us-gaap:CommonClassAMember us-gaap:IPOMember 2025-07-10 0002043766 us-gaap:CommonClassAMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2025-07-10 0002043766 gteru:SponsorAndPrivatePlacementInvestorMember gteru:PrivatePlacementUnitMember 2025-07-10 2025-07-10 0002043766 gteru:SponsorAndPrivatePlacementInvestorMember us-gaap:CommonClassAMember 2025-07-10 2025-07-10 0002043766 gteru:SponsorAndPrivatePlacementInvestorMember 2025-07-10 0002043766 gteru:SponsorAndPrivatePlacementInvestorMember us-gaap:OverAllotmentOptionMember 2025-07-10 2025-07-10 0002043766 us-gaap:InvestorMember gteru:PrivatePlacementSecuritiesMember 2025-07-10 2025-07-10 0002043766 us-gaap:InvestorMember gteru:PrivatePlacementUnitMember 2025-07-10 2025-07-10 0002043766 us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-07-10 2025-07-10 0002043766 us-gaap:InvestorMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementInvestorMember gteru:PrivatePlacementSecuritiesMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementInvestorMember gteru:PrivatePlacementUnitMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementInvestorMember us-gaap:CommonClassAMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementInvestorMember 2025-07-10 0002043766 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2025-07-10 2025-07-10 0002043766 us-gaap:InvestorMember 2025-07-10 0002043766 gteru:FounderSharesOneMember 2025-07-10 2025-07-10 0002043766 gteru:PrivatePlacementWarrantsMember 2025-07-10 0002043766 gteru:PrivatePlacementRightMember 2025-07-10 0002043766 gteru:FounderSharesOneMember gteru:SponsorAndPrivatePlacementInvestorMember 2025-07-10 2025-07-10 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-10-18 2024-10-18 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember 2025-03-25 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:CommonClassBMember 2026-09-30 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:CommonClassBMember 2025-03-25 2025-03-25 0002043766 srt:MaximumMember gteru:FounderSharesOneMember us-gaap:OverAllotmentOptionMember 2025-03-25 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:OverAllotmentOptionMember 2025-03-25 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember 2025-05-14 2025-05-14 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember 2025-06-11 2025-06-11 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember 2025-05-30 2025-05-30 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember 2026-01-01 2026-09-30 0002043766 gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0002043766 srt:MinimumMember gteru:FounderSharesOneMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2026-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2025-07-10 2025-07-10 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2026-07-01 2026-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2025-07-01 2025-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2026-01-01 2026-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2025-01-01 2025-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2026-09-30 0002043766 gteru:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2025-12-31 0002043766 us-gaap:InvestorMember 2025-04-16 0002043766 us-gaap:InvestorMember 2025-06-12 0002043766 srt:MaximumMember gteru:ConvertiblePromissoryNoteMember us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2026-01-01 2026-09-30 0002043766 gteru:ConvertiblePromissoryNoteMember us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2026-09-30 0002043766 gteru:ConvertiblePromissoryNoteMember us-gaap:InvestorMember 2026-09-30 0002043766 gteru:ConvertiblePromissoryNoteMember us-gaap:InvestorMember 2025-12-31 0002043766 gteru:PromissoryNoteMember gteru:SponsorMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:PromissoryNoteMember gteru:SponsorMember us-gaap:SubsequentEventMember 2026-11-12 2026-11-12 0002043766 gteru:AdvisorMember 2025-07-10 2025-07-10 0002043766 gteru:AdvisorOneMember 2025-07-10 2025-07-10 0002043766 gteru:AdvisorOneMember 2025-05-30 2025-05-30 0002043766 us-gaap:OverAllotmentOptionMember 2025-07-09 2025-07-09 0002043766 us-gaap:IPOMember 2025-07-09 2025-07-09 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-30 2026-11-30 0002043766 us-gaap:CommonClassBMember 2026-01-01 2026-09-30 0002043766 us-gaap:CommonClassBMember us-gaap:OverAllotmentOptionMember 2025-07-08 2025-07-09 0002043766 us-gaap:RightsMember 2026-09-30 0002043766 us-gaap:RightsMember 2025-12-31 0002043766 gteru:PublicRightsMember 2026-09-30 0002043766 gteru:PublicRightsMember 2025-12-31 0002043766 gteru:PrivatePlacementRightsMember 2026-09-30 0002043766 gteru:PrivatePlacementRightsMember 2025-12-31 0002043766 gteru:PublicWarrantsMember 2026-09-30 0002043766 gteru:PublicWarrantsMember 2025-12-31 0002043766 gteru:PrivatePlacementWarrantsMember 2026-09-30 0002043766 gteru:PrivatePlacementWarrantsMember 2025-12-31 0002043766 gteru:PublicWarrantsAndRightMember us-gaap:CommonClassAMember 2025-07-25 0002043766 gteru:PublicWarrantsMember 2026-01-01 2026-09-30 0002043766 srt:MinimumMember gteru:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember us-gaap:CommonClassAMember 2026-09-30 0002043766 gteru:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember 2026-09-30 0002043766 gteru:RedeemableWarrantsMember 2026-09-30 0002043766 srt:MaximumMember us-gaap:CommonClassAMember 2026-09-30 0002043766 srt:MaximumMember gteru:AdditionalOfferingMember 2026-09-30 0002043766 gteru:AdditionalOfferingMember 2026-01-01 2026-09-30 0002043766 gteru:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember 2026-01-01 2026-09-30 0002043766 gteru:SingleSegmentMember 2026-09-30 0002043766 us-gaap:FairValueInputsLevel1Member 2026-09-30 0002043766 gteru:PublicWarrantsMember 2025-07-10 0002043766 gteru:PublicWarrantsMember us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-07-10 0002043766 gteru:PublicWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-07-10 0002043766 gteru:PublicWarrantsMember gteru:ProbabilityOfInitialBusinessCombinationMember 2025-07-10 0002043766 gteru:PublicWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-07-10 0002043766 gteru:PublicRightsMember 2025-07-10 0002043766 us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-10-09 0002043766 srt:MaximumMember gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-10 2026-11-10 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-10 0002043766 us-gaap:SubsequentEventMember 2026-11-10 2026-11-10 0002043766 srt:MaximumMember gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-10 2026-11-10 0002043766 srt:MaximumMember us-gaap:SubsequentEventMember 2026-11-10 2026-11-10 0002043766 us-gaap:SubsequentEventMember 2026-11-10 0002043766 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-11-08 2026-11-08 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-08 2026-11-08 0002043766 gteru:PublicWarrantsAndRightMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:BCLtdMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 srt:MaximumMember gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 us-gaap:SubsequentEventMember 2026-11-08 2026-11-08 0002043766 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-11-08 0002043766 srt:MaximumMember gteru:FounderSharesOneMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 srt:MaximumMember gteru:PublicSharesMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:SponsorMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-11-08 0002043766 gteru:SponsorMember us-gaap:SubsequentEventMember 2026-11-12 2026-11-12 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-11-12 2026-11-12 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-10-09 0002043766 gteru:NaturesLedgerIncOneMember us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0002043766 gteru:NaturesLedgerIncTwoMember us-gaap:SubsequentEventMember 2026-10-09 0002043766 gteru:NaturesLedgerIncTwoMember us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0002043766 gteru:NaturesLedgerIncMember us-gaap:SubsequentEventMember 2026-11-09 2026-11-09 0002043766 gteru:NaturesLedgerIncMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-11-12 2026-11-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares gteru:Business gteru:Investors xbrli:pure gteru:Demand gteru:Vote gteru:Segment gteru:Decimal

Keep reading